

**(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)**

**(19) World Intellectual Property Organization**  
International Bureau



**(43) International Publication Date**  
**10 October 2002 (10.10.2002)**

**PCT**

**(10) International Publication Number**  
**WO 02/078730 A2**

**(51) International Patent Classification<sup>7</sup>:** **A61K 38/00**

**(21) International Application Number:** **PCT/US02/06388**

**(74) Agent:** **ELRIFI, Ivor, R.**; Mintz, Levin, Cohn, Ferris,, Glovsky and Popeo, P.C., One Financial Center, Bosotn, MA 02111 (US).

**(22) International Filing Date:** 28 February 2002 (28.02.2002)

**(81) Designated States (national):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

**(25) Filing Language:**

English

**(26) Publication Language:**

English

**(30) Priority Data:**

60/287,554 28 March 2001 (28.03.2001) US  
09/820,421 28 March 2001 (28.03.2001) US

**(84) Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:**

US 09/820,421 (CIP)  
Filed on 28 March 2001 (28.03.2001)

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

**(71) Applicant (for all designated States except US):** **BIOGEN, INC.** [US/US]; 14 Cambridge Center, Cambridge, Massachusetts 02142 (US).

**(72) Inventor; and**

**(75) Inventor/Applicant (for US only):** **SAH, Dinah, W., Y.** [US/US]; 4 Longfellow Place, Apt. 2608, Boston, MA 02114 (US).



**WO 02/078730 A2**

**(54) Title:** TREATMENT USING NEUBLASTIN POLYPEPTIDES

**(57) Abstract:** The invention relates to treatments of neuropathic pain, including tactile allodynia, and to treatments for reducing loss of pain sensitivity associated with neurophathy. The present treatments involve the use of neublastin (NBN) polypeptides.

## TREATMENT USING NEUBLASTIN POLYPEPTIDES

### FIELD OF THE INVENTION

The invention relates to treatments for neuropathic pain, including tactile allodynia,  
5 and to treatments for reducing loss of pain sensitivity associated with neuropathy.

### BACKGROUND OF THE INVENTION

Neuropathic pain is a category of pain that includes several forms of chronic pain and which results from dysfunction of nervous rather than somatic tissue. Neuropathic pain, that is pain deriving from dysfunction of the central or peripheral nervous system, may also be a  
10 consequence of damage to peripheral nerves or to regions of the central nervous system, may result from disease, or may be idiopathic. Symptoms of neuropathic pain include sensations of burning, tingling, electricity, pins and needles, stiffness, numbness in the extremities, feelings of bodily distortion, allodynia (pain evoked by stimulation of the skin that is normally innocuous), hyperalgesia (abnormal sensitivity to pain), and hyperpathia (an exaggerated pain  
15 response persisting long after the pain stimuli cease).

Several common causes of neuropathic pain are diabetes, cancer chemotherapy, herpes zoster infection, cervical or lumbar root compression owing to degenerative spine disease, malignant lesions of nerve plexus or root, nerve degeneration, such as from amputation, HIV infection, and lesions of central pain pathways, including the spinothalamic tract, thalamus, or  
20 thalamic radiations. Additional causes of neuropathic pain include drug-induced, or toxin-induced neuropathies. For example, antivirals such as ddI, ddC and d4T commonly cause peripheral neuropathies, as do phenytoin (a seizure medication), isoniazid (a tuberculosis medication), vincristine, vinblastine, taxol, taxotere and cisplatin (cancer chemotherapeutic agents), high dose vitamins, and folic acid antagonists.

25 Current therapies for the management of neuropathic pain are of limited benefit to many patients, and involve undesirable side effects or dose-limiting toxicities. In addition, current therapies are symptomatic, not disease modifying. Needs remain for improved therapies for the management and treatment of neuropathic pain, especially those that target the underlying pathology.

## SUMMARY OF THE INVENTION

This invention provides improved methods for treating neuropathic pain, for treating tactile allodynia and for reducing loss of pain sensitivity associated with neuropathy. The present methods use neublastin (“NBN”) polypeptides, including full-length neublastin

5 polypeptides or bioactive truncated neublastin polypeptides, including, *e.g.*, at least SEQ ID NOS:2, 4, 5 and 11-27. In addition, the invention provides pharmaceutical compositions containing a full-length neublastin polypeptide or a truncated neublastin polypeptide suspended, dissolved, or dispersed in a pharmaceutically acceptable carrier.

In a specific embodiment, the neublastin polypeptide may be any polypeptide of

10 AA<sub>80</sub>-AA<sub>140</sub> of SEQ ID NO:2, AA<sub>41</sub>-AA<sub>140</sub> of SEQ ID NO:2, AA<sub>1</sub>-AA<sub>140</sub> of SEQ ID NO:2, AA<sub>25</sub>-AA<sub>140</sub> of SEQ ID NO:2, AA<sub>28</sub>-AA<sub>140</sub> of SEQ ID NO:2, AA<sub>80</sub>-AA<sub>144</sub> of SEQ ID NO:4, AA<sub>1</sub>-AA<sub>144</sub> of SEQ ID NO:4, AA<sub>1</sub>-AA<sub>224</sub> of SEQ ID NO:5, or AA<sub>81</sub>-AA<sub>224</sub> of SEQ ID NO:5; at least one polypeptide comprising the C-terminal sequence set forth in either AA<sub>107</sub>-AA<sub>140</sub> of SEQ ID NO:2 or AA<sub>76</sub>-AA<sub>140</sub> of SEQ ID NO:2, and which retain the seven Cys residues  
15 characteristic of the GDNF family and of the TGF-beta super family; at least one polypeptide comprising SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26 or SEQ ID NO:27; or at least one polypeptide sequence that has greater than 70% amino acid homology to a sequence listed above.

20 The neublastin polypeptide may be modified by a derivative moiety to have an extended residence time and or increased concentration in the body. The neublastin polypeptides may be N-glycosylated neublastin polypeptides. In addition, the neublastin polypeptide may be derivatized with one or more moieties including, but not limited to, polyethylene glycol moieties, aliphatic esters, amides, N-acyl-derivatives, or O-acyl derivatives.

25 In one embodiment, the invention features a method for treating neuropathic pain in a subject comprising administering to the subject an effective amount of a neublastin polypeptide, including, *e.g.*, any one of SEQ ID NOS:2, 4, 5 and 11-27, either alone, or by also administering to the subject an effective amount of an analgesia-inducing compound selected from the group consisting of opioids, anti-arrhythmics, topical analgesics, local anaesthetics,  
30 anticonvulsants, antidepressants, corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDS). In a preferred embodiment, the analgesia-inducing compound is an anticonvulsant. In another preferred embodiment, the analgesia-inducing compound is gabapentin

((1-aminomethyl)cyclohexane acetic acid) or pregabalin (S-(+)-4-amino-3-(2-methylpropyl)butanoic acid).

In another embodiment, the invention features a method for treating tactile allodynia in a subject, either by administering to the subject an effective amount of a neublastin

5 polypeptide, including, *e.g.*, at least one of SEQ ID NOS:2, 4, 5 and 11-27, either alone, or by administering to the subject an effective amount of a neublastin polypeptide with an effective amount of an analgesia-inducing compound selected from the group consisting of opioids, anti-arrhythmics, topical analgesics, local anaesthetics, anticonvulsants, antidepressants, corticosteroids and NSAIDS. In a preferred embodiment, the analgesia-inducing compound is  
10 an anticonvulsant. In another preferred embodiment, the analgesia-inducing compound is gabapentin ((1-aminomethyl)cyclohexane acetic acid) or pregabalin (S-(+)-4-amino-3-(2-methylpropyl)butanoic acid).

Neublastin polypeptide may be administered in association with a therapeutic agent,

including but not limited to an anti-cancer agent or an anti-viral agent. Anti-cancer agents

15 include, but are not limited to, taxol, taxotere, cisplatin, nocodazole, vincristine, vindesine and vinblastine. Anti-viral agents include, but are not limited to, ddI, DDC, d4T, foscarnet, dapsone, metronidazole, and isoniazid.

The invention includes a method for treating neuropathic pain in a subject. In a specific embodiment, the neuropathic pain is associated with diabetic neuropathy. In another

20 embodiment, the neuropathic pain is associated with infection of a subject by a virus, including but not limited to a herpes virus, a human immunodeficiency virus (HIV), and a papilloma virus. Neuropathic pain may be associated with infection by a herpes zoster virus, or especially with post-herpetic neuralgia. In a further embodiment, the neuropathic pain is associated with sciatica. In another embodiment, the invention features a method for modulating the loss of  
25 pain sensitivity in a subject afflicted with a neuropathy. In a preferred embodiment, the neuropathy is diabetic neuropathy. In another preferred embodiment, the loss of pain sensitivity is a loss in thermal pain sensitivity.

In further embodiments, the neuropathic pain is hyperalgesic pain, phantom pain, thermal hyperalgesia, or due to injury associated with trauma. In addition, neuropathic pain

30 may also be associated with hereditary neuropathy (including but not limited to Friedreich ataxia, familial amyloid polyneuropathy, Tangier disease, Fabry disease), metabolic disorders (including but not limited to renal insufficiency and hypothyroidism), vitamin deficiencies

(including but not limited to vitamin B12 deficiency, vitamin B6 deficiency, and vitamin E deficiency), toxic and iatrogenic neuropathies (including but not limited to alcoholism, vitamin B6 intoxication, hexacarbon intoxication, amiodarone, chloramphenicol, disulfiram, isoniazide, gold, lithium, metronidazole, misonidazole, nitrofurantoin), infectious neuropathies (including  
5 but not limited to leprosy, Lyme disease), auto-immune neuropathies (including but not limited to Guillain-Barre syndrome, chronic inflammatory de-myelinating polyneuropathy, monoclonal gammopathy of undetermined significance and polyneuropathy), trigeminal neuralgia, entrapment syndromes (including but not limited to Carpel tunnel), post-traumatic neuralgia, phantom limb pain, multiple sclerosis pain, complex regional pain syndromes (including but  
10 not limited to reflex sympathetic dystrophy, causalgia), neoplasia, vasculitic/angiopathic neuropathy and idiopathic neuropathy.

The foregoing methods contemplate administering to the subject, preferably systemically, a formulation comprising a neublastin polypeptide at a dosage of between 1 µg/kg to 30,000 µg/kg body weight of the subject, per dose. In alternative embodiments, the  
15 dosage is between 10 µg/kg to 30,000 µg/kg body weight of the subject, per dose; between 10 µg/kg to 10,000 µg/kg body weight of the subject, per dose; between 25 µg/kg to 10,000 µg/kg body weight of the subject, per dose; between 25 µg/kg to 3,000 µg/kg body weight of the subject, per dose; and between 50 µg/kg to 3,000 µg/kg body weight of the subject, per dose.

The neublastin polypeptide used in the foregoing methods can be administered via any  
20 suitable delivery system, and preferably from the group consisting of intravenous delivery, intramuscular delivery, intrapulmonary delivery, subcutaneous delivery, and intraperitoneal delivery, most preferably via intramuscular delivery or subcutaneous delivery. The neublastin polypeptide used in the foregoing methods can also be administered via intrathecal delivery.

The NBN polypeptide-containing formulation of the invention may be administered in a  
25 timed-released composition.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, suitable methods and materials are described  
30 below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification,

including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

5

### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a broken line plot illustrating near complete prevention of tactile allodynia by subcutaneous neublastin (NBN) in rats with L5/L6 spinal nerve ligation (SNL);

FIG. 2 is a broken line plot illustrating near complete prevention of thermal hyperalgesia by subcutaneous neublastin (NBN) in rats with L5/L6 spinal nerve ligation (SNL).

10

FIG. 3 is a broken line plot illustrating the near complete reversal of fully established tactile allodynia by subcutaneous neublastin (NBN) in rats with L5/L6 spinal nerve ligation (SNL);

15

FIG. 4 is a broken line plot illustrating the near complete reversal of fully established thermal hyperalgesia by subcutaneous neublastin (NBN) in rats with L5/L6 spinal nerve ligation (SNL).

FIG. 5 is a bar graph illustrating near complete normalization of thermal hypoalgesia by subcutaneous neublastin in rats with STZ (streptozotocin) -induced neuropathy.

20

FIG. 6A and FIG. 6B are graphic representations illustrating the prevention of thermal hyperalgesia (FIG. 6A), prevention of thermal hypoalgesia (FIG. 6B), and reversal of thermal hyperalgesia (FIG. 6B) by subcutaneous neublastin in rats with STZ (streptozotocin) - induced neuropathy at 4 weeks (FIG. 6A) and 8 weeks (FIG. 6B) post STZ treatment.

FIG. 7 is a broken line plot illustrating dose-dependent neublastin (NBN) reversal of fully established tactile allodynia by subcutaneous neublastin in rats with L5/L6 spinal nerve ligation (SNL).

25

FIG. 8 is a broken line plot illustrating dose-dependent neublastin (NBN) reversal of fully established thermal hyperalgesia by subcutaneous neublastin in rats with L5/L6 spinal nerve ligation (SNL).

### DETAILED DISCLOSURE OF THE INVENTION

This invention relates to methods and compositions for treating neuropathic pain, for 30 treating tactile allodynia and for reducing loss of pain sensitivity by administering a neublastin polypeptide to a subject at risk of, or afflicted with, neuropathic pain.

Neublastin polypeptides are proteins which promote survival, maintain phenotypic differentiation, prevent degeneration, promote regeneration, and restore the activity of neuronal cells and tissues. Neublastin (initially described, *e.g.*, in WO 00/01815) has alternately been referred to as "artemin" (see, *e.g.*, WO 00/18799) and "enovin" (see, *e.g.*, WO 00/04050).

- 5 Neublastin has been classified as a distant member of the TGF- $\beta$  superfamily (Massague, *et al.*, 1994, *Trends in Cell Biology*, 4: 172-178) and is a member of glial cell line-derived neurotrophic factor ligand family ("GDNF"; WO 93/06116, incorporated herein by reference), in the family which includes GDNF, persephin ("PSP" ; Milbrandt *et al.*, 1998, *Neuron* 20:245-253, incorporated herein by reference) and neurturin ("NTN"; WO 97/08196, incorporated 10 herein by reference). The ligands of the GDNF subfamily have in common their ability to induce signalling through the RET receptor tyrosine kinase. These three ligands of the GDNF subfamily differ in their relative affinities for a family of neurotrophic receptors, the GFR $\alpha$  receptors. Neublastin acts preferably through the GFR $\alpha$ 3 - RET complex. Baudet *et al.*, *Development*, 127, pp. 4335-44 (2000); Baloh *et al.*, *Neuron*, 21, pp. 1291-1302 (1998); 15 Airaksinen *et al.*, *Mol. Cell. Neuroscience*, 13, pp. 313-325 (1999).

An amino acid sequence comparison of Neublastin (SEQ ID NO:2) to the GDNF subfamily members Neurturin (SEQ ID NO:6), Persephin (SEQ ID NO:7) and GDNF (SEQ ID NO:8) is shown in Table 1. Neublastin polypeptides useful in this invention preferably hold the GDNF subfamily fingerprint, *i.e.* the amino acid residues underlined in Table 1.

20

**Table 1:**

**Amino Acid Sequence Comparison of Neublastin (SEQ ID NO:2) to Neurturin (SEQ ID NO:6), Persephin (SEQ ID NO:7), and GDNF (SEQ ID NO:8)**

Neurturin-full	-----MQRWKAALASVLCSSVLSIWMCREGLLLSHRLGPA
Neublastin	MELGLGGILSTLSHCPWPRRQPALWPTLAALALLSSVAEASLGSPAPREGPPP
Persephin-full	-----
GDNF_HUMAN-full	-----MKLWDVVAVCLVLLHTASFPLPAGKRPPEAPAEDRSLGRRRAPFALSSDS
Neurturin-full	LVPLHLRLPRTLDARIARLAQYRALLQGAPDAMELRELTPWAGRPPGPRRRAGP RR
Neublastin	VLASPAGHLPGGRTARWCSGRARRPPPQPSRPAPPPPAPPSALPRGGRAARAGGPG
Persephin-full	-MAVGKFLLGSLLLLSLLQLQGQGWGP DARGVPVADGEFSSEQVAKAGGTWLGH RPL
GDNF_HUMAN-full	NMPEDYPDQFDVMDFIQATIKRLKRSPDKQMAVLPRRERNRQAAA NPENSRGKG
Neurturin-full	RARARLGA PCGLRELEV RVSEL <u>GLGY</u> ASDET VL <u>FRYCA GACEA</u> -AARVYDLGLRR
Neublastin	SRARAAGARGC RLRSQLPV RAL <u>GLGH</u> RSDEL VR <u>FRFC</u> <u>SGC</u> R-ARS PHDLSL IAS
Persephin-full	ARLRRALSG PCQLWSLT SVAE <u>GLGY</u> ASEEK VI <u>FRYCA GSC</u> PRGART QHGLALAR
GDNF_HUMAN-full	RRGQRGKN RCVLT AIHLNV TD <u>GLGY</u> ETKEELI <u>FRYCS GSC</u> DA-AETTY DKILKN
	* * : * *** : : * : * : * : * : * : * : . *

Neurturin-full	LRQRRLRRE --- RVRAQ <b>PCCRP</b> TAYEDEVSFLDAHSRYHTVHELSARECACV-
Neublastin	LLGAGALRPPPGSRPV <b>SQPCCRPT</b> RYE - AVSFMDVNSTWRTVDRL <u>SATACGCLG</u>
Persephin-full	LQQGGRAHGG ----- <b>PCCRPT</b> RTY-T-DVAFLDDRHRWQRLPQL <u>SAAACGC</u> GG
GDNF_HUMAN-full	LSRNRRLVSD --- KVG <b>QACCRP</b> IAFDDDSLFLDDNLVYHILRKHS <u>AKRCGCI</u> -
	*
	***** : : : * : . : : : . * * . *

- \* indicates positions which have a single, fully conserved residue.  
 : indicates that one of the following 'strong' groups is fully conserved:  
 -STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW.  
 . indicates that one of the following 'weaker' groups is fully conserved:  
 -CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK, NDEQHK, NEQHRK, HFY.

From the amino acid sequence alignment shown in Table 1, it can be seen that neublastin has seven cysteine residues at locations that are conserved within the TGF- $\beta$  superfamily. Based on this sequence alignment, neublastin was shown to be a member of the 5 GDNF subfamily of neurotrophic factors (LGLG - FR(Y/F)CSGSC - QxCCRP - SAxxCGC, the GDNF subfamily fingerprint, underlined in Table 1).

The neublastin polypeptides useful herein may be provided in any bioactive form, including the form of pre-pro-proteins, pro-proteins, mature proteins, glycosylated proteins, phosphorylated proteins, truncated forms, or any other post-translationally modified protein. It 10 is assumed that a bioactive neublastin is in the dimerized form for each NBN variant, because dimer formation is required for activity. Little to no activity is observed in a monomeric NBN polypeptide. A bioactive neublastin polypeptide includes a dimerized polypeptide that, in the presence of a cofactor (such as GFR $\alpha$ 3 or RET), binds to GFR $\alpha$ 3 or to a complex of GFR $\alpha$ 3 and RET, induces dimerization of RET, and autophosphorylation of RET. Accordingly, a 15 "neublastin polypeptide," as used herein, is a polypeptide which possesses neurotrophic activity (e.g., as described in WO 00/01815) as follows:

### 1. Wild-type Neublastin

The following "wild-type" neublastin amino acid ("aa" or "AA") sequences are exemplary of those that are useful in the methods and compositions of this invention:

- 20 -- AA<sub>80</sub>-AA<sub>140</sub> of SEQ ID NO:2 ("wild type" human prepro),  
 -- AA<sub>41</sub>-AA<sub>140</sub> of SEQ ID NO:2 (pro human),  
 -- AA<sub>1</sub>-AA<sub>140</sub> of SEQ ID NO:2 (mature 140AA (SEQ ID NO:11); hereafter  
 "140NBN"),

-- AA<sub>25</sub>-AA<sub>140</sub> of SEQ ID NO:2 (mature 116AA (SEQ ID NO:12); hereafter "116NBN"),

-- AA<sub>28</sub>-AA<sub>140</sub> of SEQ ID NO:2 (mature 113AA (SEQ ID NO:13); hereafter "113NBN"),

5 -- AA<sub>80</sub>-AA<sub>144</sub> of SEQ ID NO:4 (murine prepro),

-- AA<sub>1</sub>-AA<sub>144</sub> of SEQ ID NO:4 (murine mature -- 144 AA),

-- AA<sub>1</sub>-AA<sub>224</sub> of SEQ ID NO:5 (rat prepro),

-- AA<sub>81</sub>-AA<sub>224</sub> of SEQ ID NO:5 (rat mature -- 144 AA),

10 -- Peptides with a C-terminal sequence set forth in AA<sub>107</sub>-AA<sub>140</sub> of SEQ ID NO:2, more preferably AA<sub>76</sub>-AA<sub>140</sub> of SEQ ID NO:2, and which retain the 7 Cys residues characteristic of the GDNF family and of the TGF- $\beta$  super family.

In one embodiment, the preferred neublastin polypeptide contains (seven) cysteines conserved as in SEQ ID NO:2 at positions 43, 70, 74, 107, 108, 136 and 138. These seven conserved cysteine residues are known within the TGF-  $\beta$  superfamily to form three

15 intramonomeric disulfide bonds (contemplated, e.g., in SEQ ID NO:2 between cysteine residues 43-108, 70-136, and 74-138) and one intermonomeric disulfide bond (contemplated, e.g., in SEQ ID NO:2 between cysteine residues 107-107), which together with the extended beta strand region constitutes the conserved structural motif for the TGF-  $\beta$  superfamily. See, e.g., Daopin *et al.*, *Proteins* 1993, 17: 176-192.

20 **2. Truncated Neublastins ("NBNs")**

Neublastin polypeptides useful in the present invention also include truncated forms of the full length neublastin molecule. In such truncated molecules, one or more amino acids have been deleted from the N-terminus or the C-terminus, preferably the N-terminus. The truncated neublastin polypeptide may be obtained by providing a mature neublastin polypeptide 25 and contacting the mature neublastin polypeptide with at least one protease under conditions sufficient to produce the truncated neublastin polypeptide. Preferably, at least one protease is an exoprotease, and contacting the mature neublastin polypeptide results in formation of an exopeptidase neublastin polypeptide digestion product that can be further digested with a dipeptidyl peptidase.

30 The truncated neublastin polypeptides described herein preferably include a polypeptide sequence that encompasses the seven cysteine residues conserved in the mature neublastin

sequence. In certain preferred embodiments, the truncated neublastin polypeptide includes at least the 85 carboxy terminal amino acids of mature 113NBN neublastin polypeptide.

Other variants of Neublastin include truncated NBN forms. Examples of these include:

(i) the 112AA polypeptide sequence designated herein as NBN112, which possesses

5 the carboxy terminal 112 amino acids of a mature neublastin polypeptide, *e.g.*, amino acids 29-140 of SEQ ID NO:2 (SEQ ID NO:14).

(ii) the 111AA polypeptide sequence designated herein as NBN111, which possesses

the carboxy terminal 111 amino acids of a mature neublastin polypeptide, *e.g.*, amino acids 30-140 of SEQ ID NO:2 (SEQ ID NO:15).

10 (iii) the 110AA polypeptide sequence designated herein as NBN110, which possesses the carboxy terminal 110 amino acids of a mature neublastin polypeptide, *e.g.*, amino acids 31-140 of SEQ ID NO:2 (SEQ ID NO:16).

(iv) the 109AA polypeptide sequence designated herein as NBN109, which possesses the carboxy terminal 109 amino acids of a mature neublastin polypeptide, *e.g.*,

15 amino acids 32-140 of SEQ ID NO:2 (SEQ ID NO:17).

(v) the 108AA polypeptide sequence designated herein as NBN108, which possesses the carboxy terminal 108 amino acids of a mature neublastin polypeptide, *e.g.*, amino acids 33-140 of SEQ ID NO:2 (SEQ ID NO:18).

20 (vi) the 107AA polypeptide sequence designated herein as NBN107, which possesses the carboxy terminal 107 amino acids of a mature neublastin polypeptide, *e.g.*, amino acids 34-140 of SEQ ID NO:2 (SEQ ID NO:19).

(vii) the 106AA polypeptide sequence designated herein as NBN106, which possesses the carboxy terminal 106 amino acids of a mature neublastin polypeptide, *e.g.*, amino acids 35-140 of SEQ ID NO:2 (SEQ ID NO:20).

25 (viii) the 105AA polypeptide sequence designated herein as NBN105, which possesses the carboxy terminal 105 amino acids of a mature neublastin polypeptide, *e.g.*, amino acids 36-140 of SEQ ID NO:2 (SEQ ID NO:21).

- (ix) the 104AA polypeptide sequence designated herein as NBN104, which possesses the carboxy terminal 104 amino acids of a mature neublastin polypeptide, *e.g.*, amino acids 37-140 of SEQ ID NO:2 (SEQ ID NO:22).
- 5 (x) the 103AA polypeptide sequence designated herein as NBN103, which possesses the carboxy terminal 103 amino acids of a mature neublastin polypeptide, *e.g.*, amino acids 38-140 of SEQ ID NO:2 (SEQ ID NO:23).
- (xi) the 102AA polypeptide sequence designated herein as NBN102, which possesses the carboxy terminal 102 amino acids of a mature neublastin polypeptide, *e.g.*, amino acids 39-140 of SEQ ID NO:2 (SEQ ID NO:24).
- 10 (xii) the 101AA polypeptide sequence designated herein as NBN101, which possesses the carboxy terminal 101 amino acids of a mature neublastin polypeptide, *e.g.*, amino acids 40-140 of SEQ ID NO:2 (SEQ ID NO:25).
- (xiii) the 100AA polypeptide sequence designated herein as NBN100, which possesses the carboxy terminal 100 amino acids of a mature neublastin polypeptide, *e.g.*, amino acids 41-140 of SEQ ID NO:2 (SEQ ID NO:26).
- 15 (xiv) the 99AA polypeptide sequence designated herein as NBN99, which possesses the carboxy terminal 99 amino acids of a mature neublastin polypeptide, *e.g.*, amino acids 42-140 of SEQ ID NO:2 (SEQ ID NO:27).

It is understood that the truncated forms of Neublastin disclosed herein (*e.g.*, the 20 112AA through 99AA forms) have neurotrophic activity.

In most preferred embodiments, the truncated neublastin polypeptide is the 99 aa, 100 aa, 101 aa, 102 aa, 103 aa, 104 aa, 105 aa, 106 aa, 107 aa, 108 aa, 109 aa, 110 aa, 111 aa or 112 aa carboxy terminal amino acids of mature 113 AA neublastin polypeptide (*i.e.*, NBN99, NBN100, NBN101, NBN102, NBN103, NBN104, NBN105, NBN106, NBN107, NBN108, 25 NBN109, NBN110, NBN111 or NBN112, respectively). The sequences may also be found in the murine and rat neublastin polypeptides as the carboxy terminal 99 aa, 100 aa, 101 aa, 102 aa, 103 aa, 104 aa, 105 aa, 106 aa, 107 aa, 108 aa, 109 aa, 110 aa, 111 aa or 112 aa, respectively, in SEQ ID NOS:4 and 5. These most preferred examples of truncated NBN forms are bioactive (referred to “bioactive truncated neublastin polypeptides”) as they have been 30 demonstrated herein to have neurotrophic activity. As stated above, NBN dimerization is

required for bioactivity, as little to no activity is observed with the NBN monomeric polypeptide.

### 3. Variant Neublastins (“NBNs”) With Substantial Similarity or Identity

The NBNs useful in this invention also include those NBN polypeptides that have an amino acid sequence with substantial similarity or identity to the various prepro, pro, mature and truncated “neublastin” polypeptides set forth above. Preferably the neublastin polypeptide used has at least 70%, more preferably 85%, still more preferably 90%, or still further preferably 95% identity or similarity to the neublastin polypeptides in SEQ ID NOS:2, 4, 5 or 11-27. Most preferably the neublastin polypeptide used has at least 99% similarity or identity to the neublastin polypeptides in SEQ ID NOS:2, 4, 5 or 11-27.

The degree to which a candidate polypeptide shares homology with a neublastin polypeptide of the invention is determined as the degree of similarity or identity between two amino acid sequences.

A high level of sequence identity indicates a likelihood that the first sequence is derived from the second sequence. Amino acid sequence identity requires identical amino acid sequences between two aligned sequences. Thus, a candidate sequence sharing 70% amino acid identity with a reference sequence, requires that, following alignment, 70% of the amino acids in the candidate sequence are identical to the corresponding amino acids in the reference sequence. Identity is determined by computer analysis, such as, without limitations, the ClustalX computer alignment program (Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, & Higgins DG: “The ClustalX windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools”; *Nucleic Acids Res.* 1997, **25** (24): 4876-82), and the default parameters suggested therein. Using this program, the mature part of a polypeptide encoded by an analogous DNA sequence of the invention exhibits a degree of identity of at least 70%, more preferably 85%, still more preferably 90%, or still further preferably 95%, most preferably at least 99% with the amino acid sequences presented herein as SEQ ID NO:2 (human NBN), SEQ ID NOS:4 and 5 (rodent NBN), or SEQ ID NOS:11-27 (mature and truncated NBN).

Other alignment tools are known, such as the dynamic programming algorithm described in Needleman *et al.*, *J. Mol. Biol.* 48: 443 (1970), and the Align Program, a commercial software package produced by DNAsstar, Inc. the teachings of which are

incorporated by reference herein. Once the alignment between the candidate and reference sequence is made and refined, a percent homology score is calculated. The individual amino acids of each sequence are compared sequentially according to their similarity to each other.

Similarity factors include similar size, shape and electrical charge. One particularly

- 5 preferred method of determining amino acid similarities is the PAM250 matrix described in Dayhoff *et al.*, ATLAS OF PROTEIN SEQUENCE AND STRUCTURE 345-352 (1978 & Supp.), incorporated by reference herein. A similarity score is first calculated as the sum of the aligned pairwise amino acid similarity scores. Insertions and deletions are ignored for the purposes of percent homology and identity. Accordingly, gap penalties are not used in this calculation.
- 10 The raw score is then normalized by dividing it by the geometric mean of the scores of the candidate compound and the seven cysteine skeleton of the neublastin polypeptides. The geometric mean is the square root of the product of these scores. The normalized raw score is the percent homology.

As noted above, the neublastin polypeptides of the invention include variant

- 15 polypeptides. In the context of this invention, the term “variant polypeptide” includes a polypeptide (or protein) having an amino acid sequence that differs from the sequences presented as SEQ ID NO:2 (human NBN), or SEQ ID NOS:4 and 5 (rodent NBN), or SEQ ID NOS:11-27 (mature and truncated NBN), at one or more amino acid positions. Such variant polypeptides include the modified polypeptides described above, as well as conservative substitutions, splice  
20 variants, isoforms, homologues from other species, and polymorphisms.

As defined herein, the term “conservative substitutions” denotes the replacement of an amino acid residue by another, biologically similar, residue. Typically, biological similarity, as referred to above, reflects substitutions on the wild type sequence with conserved amino acids.

- 25 For example, one would expect conservative amino acid substitutions to have little or no effect on the biological activity, particularly if they represent less than 10% of the total number of residues in the polypeptide or protein. Preferably, conservative amino acid substitutions represent changes in less than 5% of the polypeptide or protein, most preferably less than 2% of the polypeptide or protein. For example, when calculated in accordance, *e.g.*, with human 113NBN, most preferred conservative substitutions would represent fewer than three amino  
30 acid substitutions in the wild type mature amino acid sequence. In a particularly preferred embodiment, there is a single amino acid substitution in the mature sequence, wherein both the substituted and replacement amino acid are non-cyclic.

Other examples of particularly conservative substitutions include the substitution of one hydrophobic residue for another, such as isoleucine, valine, leucine or methionine, or the substitution of one polar residue for another, such as the substitution of arginine for lysine, glutamic for aspartic acid, or glutamine for asparagine, and the like.

5 The term conservative substitution also includes the use of a substituted amino acid residue in place of an un-substituted parent amino acid residue provided that antibodies raised to the substituted polypeptide also immunoreact with the un-substituted polypeptide.

Modifications of this primary amino acid sequence may result in proteins which have substantially equivalent activity as compared to the unmodified counterpart polypeptide, and  
10 thus may be considered functional analogs of the parent proteins. Such modifications may be deliberate, *e.g.* as by site-directed mutagenesis, or they may occur spontaneously, and include splice variants, isoforms, homologues from other species, and polymorphisms. Such functional analogs are also contemplated according to the invention.

Moreover, modifications of the primary amino acid sequence may result in proteins  
15 which do not retain the biological activity of the parent protein, including dominant negative forms, etc. A dominant negative protein may interfere with the wild-type protein by binding to, or otherwise sequestering regulating agents, such as upstream or downstream components, that normally interact functionally with the polypeptide. Such dominant negative forms are also contemplated according to the invention.

20 **4. Derivative or Modified NBNs**

Polypeptides of the present invention also include chimeric polypeptides or cleavable fusion polypeptides in which another polypeptide is fused at the N-terminus or the C-terminus of the polypeptide or fragment thereof. A chimeric polypeptide may be produced by fusing a nucleic acid sequence (or a portion thereof) encoding another polypeptide to a nucleic acid  
25 sequence (or a portion thereof) of the present invention. Techniques for producing chimeric polypeptides are standard techniques. Such techniques usually require joining the sequences such that they are in the same reading frame, and expression of the fused polypeptide under the control of the same promoter(s) and terminator.

The neublastin polypeptides may be N-glycosylated polypeptides. In one embodiment,  
30 the Asn residue at position 122 of SEQ ID NO:2 is glycosylated.

This invention also contemplates neublastin fusion proteins, such as Ig-fusions, as described, e.g., in United States patents 5,434,131; 5,565,335; 5,541,087; and 5,726,044, each herein incorporated by reference, or preferably serum albumin fusions.

The neublastin polypeptides useful here include timed-release compositions and 5 neublastin polypeptides modified with a derivative moiety (preferably a polyethylene glycol moiety) to have an extended residence time and/or increased concentration in body fluids. In addition, the neublastin polypeptide may be derivatized with a moiety selected from the group consisting of aliphatic esters, amides, N-acyl-derivatives, or O-acyl derivatives.

Table 2 below shows a ClustalW comparison between human (SEQ ID NO:2), mouse 10 (SEQ ID NO:4) and rat (SEQ ID NO:5) prepro-neublastin. Mature NBN polypeptides NBN140, NBN116, NBN113 and NBN99 are indicated by “\*”. The N-terminus of NBN112 through NBN100 are indicated by consecutive “.” symbols. Table 3 below shows distance comparison between wild type human, mouse and rat neublastin polypeptides (SEQ ID NOS:2, 4 and 5).

15

**Table 2. ClustalW comparison of Human, Mouse and Rat Neublastin**

	10	20	30	40	50	60
Human NBN	MELGLGGI	S	L	H	C	P
Mouse NBN	MELGL	E	P	T	A	L
Rat NBN	MELGLG	E	P	T	A	L
	.	.	.	.	.	.
Human NBN	PAGHLPGGRT	A	R	W	C	G
Mouse NBN	PTDHLPGGHT	A	H	L	C	S
Rat NBN	PTDYLPGGHT	A	H	L	C	S
	.	.	.	.	.	.
Human NBN	Q	R	G	R	A	G
Mouse NBN	Q	R	G	R	A	G
Rat NBN	Q	R	G	R	A	G
	*	*	:	:	:	:
	140				116	113
	70	80	90	100	110	120
Human NBN	P	A	G	H	R	G
Mouse NBN	P	T	D	H	R	G
Rat NBN	P	T	D	H	R	G
	*	*	:	:	:	:
	130	140	150	160	170	180
Human NBN	A	Y	C	R	L	R
Mouse NBN	A	T	D	A	R	R
Rat NBN	A	T	D	A	R	R
	:	:	:	*		
	99					
	190	200	210	220		
Human NBN	PPGSRP	M	S	O	P	
Mouse NBN	PPGSRP	I	S	Q	P	
Rat NBN	PPGSRP	I	S	Q	P	
	(SEQ ID NO:2)					
	(SEQ ID NO:4)					
	(SEQ ID NO:5)					

**TABLE 3: Distance comparison of Human, Mouse and Rat Neublastin**

	10	20	30	40	50	60
Human NBN	M E L G L G G L S I L S H C P W P R R Q P A L W P T L A A L A L L S S V A E A S L G S A P R S P A P R E G P P P V L A S					
Mouse NBN	A E P T A . . . . .	L R . . . . .	W . S . W . . . . .	V . . . . .	C . T . . . . .	D P M S . . . . .
Rat NBN	E P T A . . . . .	L R . . . . .	W . . . . .	T . . . . .	D P M S . . . . .	S . D V . S . . . . .
	70	80	90	100	110	120
Human NBN	P A G H L P G G R T A R W C S G R A R R R P P Q P S R P A P P P P A P P D A L P - - - R G G R A A R A G G P C S R A R					
Mouse NBN	. T D . . . . .	H . . H L . . . . .	E . . F L . . . . .	S P Q . . . . .	G . A L Q S . . . . .	P A A L . . . . .
Rat NBN	. T D Y . . . . .	H . . H L . . . . .	E . . L . . . . .	S P Q . . . . .	G . A L Q S . . . . .	P A A L . . . . .
	130	140	150	160	170	180
Human NBN	A A G A R G C R L R S Q L V P V R A L G L G H R S D E L V R F R F C S G C R R A R S P H D L S L A S L L G A G A L R P					
Mouse NBN	T T D . . . . .	S . . . . .	S . . . . .	I . . . . .	Q . . . . .	S . . . . .
Rat NBN	. T D . . . . .	S . . . . .	S . . . . .	I . . . . .		S . . . . .
	190	200	210	220		
Human NBN	P P G S R P V S Q P C C R P T R Y E A V S F M D V N S T W R T V D R L S A T A C G C L G				(SEQ ID NO:2)	
Mouse NBN	. . . . .	I . . . . .		H . . . . .		(SEQ ID NO:4)
Rat NBN	. . . . .	I . . . . .		H . . . . .		(SEQ ID NO:5)

### Methods Of Producing The Neublastin Polypeptide

The neublastin polypeptide used herein may be isolated from mammalian cells, preferably from a human cell or from a cell of murine origin. In a most preferred embodiment, 5 the neublastin polypeptide may be isolated from human heart tissue, from human skeletal muscle, from human pancreas, or from human brain tissue, in particular from caudate nucleus or from thalamus, or it may be obtained from DNA of mammalian origin, as discussed in more detail below.

Alternately, the neublastin polypeptides may be obtained by expression of 10 polynucleotides that encode such neublastin polypeptides. Such polynucleotides include DNA, cDNA and RNA sequences and are available in the art. See, e.g., WO 00/01815, WO 00/04050 and WO 00/18799, incorporated herein by reference. Particularly useful polynucleotides have the DNA sequence presented as SEQ ID NO:1 (human NBN cDNA), and the DNA sequence presented as SEQ ID NO:3 (mouse NBN cDNA). In addition, the genomic 15 sequence for human NBN may be used (see GenBank Accession No. AC 005038).

More specifically, the neublastin polypeptides useful herein may be obtained by culturing a cell containing a nucleic acid sequence encoding a neublastin polypeptide under

conditions permitting the production of the neublastin polypeptide, followed by recovery of the neublastin polypeptide from the culture medium. The nucleic acid sequence encoding a neublastin polypeptide may be a nucleic acid sequence that is normally endogenous to the cell or an exogenously-derived nucleic acid sequence that is introduced into a "production" cell.

- 5 When cells are to be genetically modified for the purposes of producing a neublastin polypeptide, the cells may be modified by conventional methods or by gene activation.

According to conventional methods, a DNA molecule that contains a neublastin cDNA or genomic DNA sequence may be contained within an expression construct and transfected into cells by standard methods including, but not limited to, liposome-, polybrene-, or DEAE dextran-mediated transfection, electroporation, calcium phosphate precipitation, microinjection, or velocity driven microprojectiles ("biolistics"). Alternatively, one could use a system that delivers DNA by viral vector. Viruses known to be useful for gene transfer include adenoviruses, adeno-associated virus, lentivirus, herpes virus, mumps virus, poliovirus, retroviruses, Sindbis virus, and vaccinia virus such as canary pox virus, as well as Baculovirus infection of insect cells, in particular Sf9 insect cells.

Alternatively, the cells may be modified to produce a neublastin polypeptide using a gene activation ("GA") approach, such as described in United States patents 5,733,761 and 5,750,376, each incorporated herein by reference.

Accordingly, the term "genetically modified," as used herein in reference to cells, is meant to encompass cells that express a particular gene product following introduction of a nucleic acid molecule encoding the gene product and/or regulatory elements that control expression of an endogenous coding sequence for the gene product. The nucleic molecule may be introduced by gene targeting, allowing incorporation of the nucleic molecule at a particular genomic site.

25 In one embodiment, the neublastin polypeptide is produced in a bacterial cell, preferably *E. coli*. In a different embodiment, the neublastin polypeptide is produced in an insect derived cell, particularly Sf9.

In another embodiment, the neublastin polypeptide is produced in, e.g., a mammalian cell, e.g., a human cell, an oocyte, or a yeast cell. The cell of the invention may be without limitation a human embryonic kidney ("HEK") cell, e.g., a HEK 293 cell, a BHK21 cell, a Chinese hamster ovary ("CHO") cell, a *Xenopus laevis* oocyte ("XLO") cell, or *Pichia pastoris* (yeast). In one embodiment, the cell of the invention is a fungal cell, e.g., a filamentous fungal

cell. In yet another embodiment, the cell is an insect cell, most preferably the Sf9 cell. Additional mammalian cells of the invention are PC12, HiB5, RN33b cell lines, human neural progenitor cells, and other cells derived from human cells, especially neural cells.

Examples of primary or secondary cells include fibroblasts, epithelial cells including  
5 mammary and intestinal epithelial cells, endothelial cells, formed elements of the blood including lymphocytes and bone marrow cells, glial cells, hepatocytes, keratinocytes, muscle cells, neural cells, or the precursors of these cell types. Examples of immortalized human cell lines useful in the present methods include, but are not limited to, Bowes Melanoma cells (ATCC Accession No. CRL 9607), Daudi cells (ATCC Accession No. CCL 213), HeLa cells  
10 and derivatives of HeLa cells (ATCC Accession Nos. CCL 2, CCL 2.1, and CCL 2.2), HL-60 cells (ATCC Accession No. CCL 240), HT-1080 cells (ATCC Accession No. CCL 121), Jurkat cells (ATCC Accession No. TIB 152), KB carcinoma cells (ATCC Accession No. CCL 17), K-562 leukemia cells (ATCC Accession No. CCL 243), MCF-7 breast cancer cells  
15 (ATCC Accession No. BTH 22), MOLT-4 cells (ATCC Accession No. 1582), Namalwa cells (ATCC Accession No. CRL 1432), Raji cells (ATCC Accession No. CCL 86), RPMI 8226 cells (ATCC Accession No. CCL 155), U-937 cells (ATCC Accession No. CRL 1593),  
WI-38VA13 sub line 2R4 cells (ATCC Accession No. CLL 75.1), and 2780AD ovarian carcinoma cells (Van der Blick *et al.*, *Cancer Res.* 48: 5927-5932, 1988), as well as heterohybridoma cells produced by fusion of human cells and cells of another species.  
20 Secondary human fibroblast strains, such as WI-38 (ATCC Accession No. CCL 75) and MRC-5 (ATCC Accession No. CCL 171), may also be used.

When the cell is an eukaryotic cell, incorporation of the heterologous polynucleotide of the invention may in particular be carried out by infection (employing a virus vector), by transfection (employing a plasmid vector), using calcium phosphate precipitation,  
25 microinjection, electroporation, lipofection, or other physical-chemical methods known in the art.

The NBN polypeptides are isolated from production cell cultures, or from culture medium conditioned by production cells, using standard protein purification techniques including refolding if applicable. Suitable techniques are described below in the Examples.

### **Subjects For Treatment**

30 This invention can be used for the treatment or prophylaxis of neuropathic pain, including tactile allodynia, and for reducing loss of pain sensitivity associated with neuropathy,

in a mammalian subject afflicted therewith, or at risk thereof. Subjects at risk of developing a neuropathy and at risk of loss of pain sensitivity associated with such neuropathy include subjects with diabetes, subjects who are receiving chemotherapy, subjects who have experienced certain traumas, subjects who have ingested various toxins or drugs, subjects 5 experiencing certain vitamin deficiencies, subjects infected with certain viral pathogens, subjects afflicted with various autoimmune disorders and metabolic disorders, and subjects who have experienced certain nerve damage or neurodegeneration. Mammalian subjects include sheep, horses, dogs, cats, pigs, rabbits, guinea pigs, rats, hamsters, gerbils and mice, but most preferably are humans.

10       Typically, in human subjects, the patient is either refractory to other traditional pain therapies, or the subject responds insufficiently to other such pain therapies to provide satisfactory pain control.

15       In general, this invention features both prophylactic treatment and therapeutic treatment protocols. In prophylactic treatment, a neublastin polypeptide is administered to a subject at risk of neuropathic pain or developing loss of pain sensitivity; such subjects would be expected to be subjects with an early stage neuropathy. The treatment with neublastin under such circumstances would serve to treat at-risk patients preventively.

20       In therapeutic treatment, a neublastin polypeptide is administered to a subject who has experienced neuropathic pain or who has experienced loss of pain sensitivity as a result of affliction with a neuropathy; such subjects would be expected to be subjects with a late stage neuropathy. The treatment with neublastin under such circumstances would serve to alleviate the neuropathic pain and/or rescue appropriate pain sensitivity in the subject. Such late stage patients may have received a number of therapies, beginning with self-medication (such as non-steroidal anti-inflammatory drugs, *e.g.*, ibuprofen). Such treatments may be escalated to 25 antidepressants (*e.g.*, tricyclic antidepressants, vanlafaxine, and selective serotonin re-uptake inhibitors -- specific medications include amitriptyline, desipramine, imipramine and nortriptyline), or anticonvulsants (*e.g.*, gabapentin, carbamazepine, lamotrigine, topiramate, and phenytoin). Other medication include topical analgesics (*e.g.*, capsaicin, and lidoderm), anti-arrhythmics and opioids. Surgery may be performed in severe neuropathy cases. Studies 30 indicate that fewer than 50% of patients respond to topical analgesics, anti-arrhythmics, opioids or surgery.

## Methods and Pharmaceutical Compositions

This invention provides methods for treating neuropathic pain, for treating tactile allodynia, and for reducing loss of pain sensitivity associated with neuropathy. The present methods use neublastin polypeptides, including full length neublastin polypeptides or bioactive truncated neublastin polypeptides. In addition, the invention provides pharmaceutical compositions containing a full length neublastin polypeptide or a truncated neublastin polypeptide suspended, dissolved, or dispersed in a pharmaceutically acceptable carrier.

### 1. Treatment of Neuropathic Pain

In one embodiment, the invention features a method for treating neuropathic pain in a subject comprising administering to the subject an effective amount of a neublastin polypeptide. The neublastin polypeptide may be administered alone (mono-therapy) or as part of a combination therapy regime. Preferred combination therapies include administering to the subject an effective amount of an analgesia-inducing compound selected from the group consisting of opioids, anti-arrhythmics, topical analgesics, local anaesthetics, anticonvulsants, antidepressants, corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDS).

The neublastin polypeptides and nucleic acids of this invention (and pharmaceutical compositions containing same described herein) are used in the treatment of pain associated with peripheral neuropathies. Among the peripheral neuropathies which can be treated according to this invention are trauma-induced neuropathies, *e.g.*, those caused by physical injury or disease state, physical damage to the brain, physical damage to the spinal cord, stroke associated with brain damage, and neurological disorders related to neurodegeneration.

The invention also provides treatments of chemotherapy-induced neuropathies (such as those caused by delivery of chemotherapeutic agents, *e.g.*, taxol or cisplatin); toxin-induced neuropathies, drug-induced neuropathies, pathogen-induced (*e.g.*, virus induced) neuropathies, vitamin-deficiency-induced neuropathies; idiopathic neuropathies; and diabetic neuropathies. See, *e.g.*, United States Patent Nos. 5,496,804 and 5,916,555, each herein incorporated by reference. The invention still further can be used for treatment of mono-neuropathies, mono-multiplex neuropathies, and poly-neuropathies, including axonal and demyelinating neuropathies, using the neublastin nucleotides and polypeptides of this invention.

The neuropathic pain may be associated with a number of peripheral neuropathies, including:

- (a) trauma-induced neuropathies,
- (b) chemotherapy-induced neuropathies,
- (c) toxin-induced neuropathies (including but not limited to neuropathies induced by alcoholism, vitamin B6 intoxication, hexacarbon intoxication, amiodarone, chloramphenicol, 5 disulfiram, isoniazide, gold, lithium, metronidazole, misonidazole, nitrofurantoin),
- (d) drug-induced neuropathies, including therapeutic drug-induced neuropathic pain (such as caused by anti-cancer agents, particularly anti-cancer agents selected from the group consisting of taxol, taxotere, cisplatin, nocodazole, vincristine, vindesine and vinblastine; and such as caused by anti-viral agents, particularly anti-viral agents selected from the group 10 consisting of ddI, DDC, d4T, foscarnet, dapsone, metronidazole, and isoniazid).
- (e) vitamin-deficiency-induced neuropathies (including but not limited to vitamin B12 deficiency, vitamin B6 deficiency, and vitamin E deficiency),
- (f) idiopathic neuropathies,
- (g) diabetic neuropathies,
- 15 (h) pathogen-induced nerve damage,
- (i) inflammation-induced nerve damage,
- (j) neurodegeneration,
- (k) hereditary neuropathy (including but not limited to Friedreich ataxia, familial amyloid polyneuropathy, Tangier disease, Fabry disease),
- 20 (l) metabolic disorders (including but not limited to renal insufficiency and hypothyroidism),
- (m) infectious and viral neuropathies (including but not limited to neuropathic pain associated with leprosy, Lyme disease, neuropathic pain associated with infection by a virus, particularly a virus selected from the group consisting of a herpes virus (*e.g.* herpes zoster 25 which may lead to post-herpetic neuralgia), a human immunodeficiency virus (HIV), and a papilloma virus),
- (n) auto-immune neuropathies (including but not limited to Guillain-Barre syndrome, chronic inflammatory de-myelinating polyneuropathy, monoclonal gammopathy of undetermined significance and polyneuropathy),
- 30 (o) trigeminal neuralgia and entrapment syndromes (including but not limited to Carpel tunnel),

(p) other neuropathic pain syndromes including post-traumatic neuralgia, phantom limb pain, multiple sclerosis pain, complex regional pain syndromes (including but not limited to reflex sympathetic dystrophy, causalgia), neoplasia- associated pain, vasculitic/angiopathic neuropathy, and sciatica.

5        Neuropathic pain may be manifested as allodynia, hyperalgesic pain, thermal hyperalgesia, or phantom pain.

## 2.        **Treatment of Tactile Allodynia**

The term “tactile allodynia” typically refers to the condition in a subject where pain is evoked by stimulation of the skin (*e.g.* touch) that is normally innocuous. This invention  
10      features a method for treating tactile allodynia in a subject.

In one embodiment, tactile allodynia is treated by administering to the subject an effective amount of a neublastin polypeptide alone.

In a second embodiment, tactile allodynia is treated by administering to the subject an effective amount of a neublastin polypeptide in combination with an effective amount of an  
15      analgesia-inducing compound selected from the group consisting of opioids, anti-arrhythmics, topical analgesics, local anaesthetics, anticonvulsants, antidepressants, corticosteroids and NSAIDS. In a preferred embodiment, the analgesia-inducing compound is an anticonvulsant. In another preferred embodiment, the analgesia-inducing compound is gabapentin ((1-aminomethyl)cyclohexane acetic acid) or pregabalin (S-(+)-4-amino-3-  
20      (2-methylpropyl)butanoic acid).

## 3.        **Treatment for Reduction of Loss of Pain Sensitivity**

In another embodiment, the invention features a method for reducing the loss of pain sensitivity in a subject afflicted with a neuropathy. In a preferred embodiment, the neuropathy is diabetic neuropathy. In a preferred embodiment, the loss of pain sensitivity is a loss in  
25      thermal pain sensitivity. This invention contemplates both prophylactic and therapeutic treatment.

In prophylactic treatment, a neublastin polypeptide is administered to a subject at risk of developing loss of pain sensitivity; such subjects would be expected to be subjects with an early stage neuropathy. The treatment with neublastin under such circumstances would serve  
30      to treat at-risk patients preventively.

In therapeutic treatment, a neublastin polypeptide is administered to a subject who has experienced loss of pain sensitivity as a result of affliction with a neuropathy; such subjects would be expected to be subjects with a late stage neuropathy. The treatment with neublastin under such circumstances would serve to rescue appropriate pain sensitivity in the subject.

5    **4. Treatment of Viral Infections and Viral-Associated Neuropathies**

Prophylactic treatment of infectious and viral neuropathies is contemplated. Prophylactic treatment is indicated after determination of viral infection and before onset of neuropathic pain. During treatment, NBN polypeptide is administered to prevent appearance of neuropathic pain including but not limited to neuropathic pain associated with leprosy, Lyme disease, neuropathic pain associated with infection by a virus, particularly a virus selected from the group consisting of a herpes virus (and more particularly by a herpes zoster virus, which may lead to post-herpetic neuralgia), a human immunodeficiency virus (HIV), and a papilloma virus). In an alternative embodiment, NBN polypeptide is administered to reduce the severity of neuropathic pain, should it appear.

15       Symptoms of acute viral infection often include the appearance of a rash. Other symptoms include, for example, the development of persistent pain in the affected area of the body, which is a common complication of a herpes zoster infection (shingles). Post-herpetic neuralgia can last for a month or more, and may appear several months after any rash-like symptoms have disappeared. Post-herpetic neuralgia may be very severe and prolonged, and  
20       can be very resistant to treatment.

5.    **Treatment of Diabetic Neuropathies**

Prophylactic treatment of diabetes associated neuropathies is contemplated. Prophylactic treatment of diabetic neuropathies would commence after determination of the initial diagnosis of diabetes or diabetes-associated symptoms and before onset of neuropathic pain. Prophylactic treatment of diabetic neuropathies may also commence upon determining that a subject is at risk for developing diabetes or diabetes-associated symptoms. During treatment, NBN polypeptide is administered to prevent appearance of neuropathic pain or reduce the severity of neuropathic pain, should it appear.

Results in FIG. 6A and FIG. 6B are relevant to treatment of diabetic neuropathy in human patients in need of such treatment. Prevention of thermal hypoalgesia and prevention and reversal of thermal hyperalgesia are contemplated, as described in Example 6.

## 6. Dosage

5 The foregoing methods contemplate administering to the subject, preferably systemically, a formulation comprising a neublastin polypeptide at a dosage of between 1  $\mu\text{g}/\text{kg}$  to 30,000  $\mu\text{g}/\text{kg}$  body weight of the subject, per dose; preferably the dosage is between 10  $\mu\text{g}/\text{kg}$  to 10,000  $\mu\text{g}/\text{kg}$  body weight of the subject, per dose; most preferably the dosage is between 25  $\mu\text{g}/\text{kg}$  to 3,000  $\mu\text{g}/\text{kg}$  body weight of the subject, per dose.

10 Various dosing regimes for treatment or prevention of tactile allodynia are contemplated. In one embodiment, methods of administering to a subject a formulation comprising a neublastin polypeptide include administering NBN at a dosage of between 1  $\mu\text{g}/\text{kg}$  to 30,000  $\mu\text{g}/\text{kg}$  body weight of the subject, per dose. In another embodiment, the dosage is between 10  $\mu\text{g}/\text{kg}$  to 30,000  $\mu\text{g}/\text{kg}$  body weight of the subject, per dose. In a further 15 embodiment, the dosage is between 10  $\mu\text{g}/\text{kg}$  to 10,000  $\mu\text{g}/\text{kg}$  body weight of the subject, per dose. In a different embodiment, the dosage is between 25  $\mu\text{g}/\text{kg}$  to 10,000  $\mu\text{g}/\text{kg}$  body weight of the subject, per dose. In yet another embodiment, the dosage is between 25  $\mu\text{g}/\text{kg}$  to 3,000  $\mu\text{g}/\text{kg}$  body weight of the subject, per dose. In a most preferable embodiment, the dosage is between 50  $\mu\text{g}/\text{kg}$  to 3,000  $\mu\text{g}/\text{kg}$  body weight of the subject, per dose.

20 Likewise, various dosing schemes for a treatment for modulating loss of pain sensitivity are contemplated. Methods of administering to a subject a formulation comprising a neublastin polypeptide include administering NBN at a dosage of between 1  $\mu\text{g}/\text{kg}$  to 30,000  $\mu\text{g}/\text{kg}$  body weight of the subject, per dose; preferably the dosage is between 10  $\mu\text{g}/\text{kg}$  to 10,000  $\mu\text{g}/\text{kg}$  body weight of the subject, per dose; most preferably the dosage is between 25  $\mu\text{g}/\text{kg}$  to 3,000 25  $\mu\text{g}/\text{kg}$  body weight of the subject, per dose.

## 7. Delivery

The neublastin polypeptide used in the foregoing methods can be administered via any suitable delivery system, and preferably from the group consisting of intravenous delivery, intramuscular delivery, intrapulmonary delivery, subcutaneous delivery, and intraperitoneal 30 delivery, most preferably via intramuscular delivery, intravenous delivery, or subcutaneous

delivery. The neublastin polypeptide used in the foregoing methods can also be administered via intrathecal delivery.

## 8. Formulation

This invention also provides novel pharmaceutical compositions comprising a 5 therapeutically effective amount of neublastin polypeptides suspended, dissolved, or dispersed in a pharmaceutically accepted carrier.

For use in therapy the polypeptide of the invention may be administered in any convenient form. In a preferred embodiment, the polypeptide of the invention is incorporated into a pharmaceutical composition together with one or more adjuvants, excipients, carriers 10 and/or diluents, and the pharmaceutical composition prepared by the skilled person using conventional methods known in the art. Further details on techniques for formulation and administration may be found in the latest edition of REMINGTON'S PHARMACEUTICAL SCIENCES (Maack Publishing Co., Easton, PA). Acceptable diluents, carriers and excipients typically do not adversely affect the recipient's homeostasis, particularly electrolyte balance. Acceptable 15 carriers can include biocompatible, inert or bioabsorbable salts, buffering agents, oligo- or polysaccharides, polymers, viscosity-improving agents, preservatives and the like. One exemplary carrier comprises normal physiologic saline (0.15 M NaCl, pH 7.0 to 7.4). Another exemplary carrier comprises 50 mM sodium phosphate, 100 mM sodium chloride.

## 9. Regimes

The frequency of dosing for the neublastin polypeptides of this invention is within the 20 skills and clinical judgement of physicians. Typically, the administration regime is established by clinical trials which may establish optimal administration parameters. However, the practitioner may vary such administration regimes according to the subject's age, health, weight, sex and medical status. The frequency of dosing may also vary between acute and 25 chronic treatments for neuropathy. In addition, the frequency of dosing may be varied depending on whether the treatment is prophylactic or therapeutic.

## EXAMPLES

### EXAMPLE 1: Expression of Neublastin Polypeptide

#### A. Expression in *E. coli*

For expression and purification in bacteria, a plasmid encoding rat neublastin was expressed in *E. coli* as a His-tagged fusion protein with an enterokinase cleavage site immediately adjacent to the start of the mature 113 amino acid NBN sequence. The *E. coli* cells were grown in a 500 L fermentor and frozen cell paste was provided. The *E. coli* cells were lysed in a Manton Gaulin Press and the rat NBN was recovered from the insoluble washed pellet fraction.

The NBN was extracted from the pellet with guanidine hydrochloride, refolded, and the His-tag removed with enterokinase. For further purification, the product was then subjected to chromatography on Ni NTA agarose (Qiagen), and to chromatography on Bakerbond WP CBX cation exchange resin.

The resulting product was subjected to extensive characterization including analysis by SDS-PAGE, size exclusion chromatography (SEC), reverse phase HPLC, matrix assisted laser desorption/ionization mass spectrometry (MALD/IMS), peptide mapping, assessment of activity in the KIRA ELISA, and determination of endotoxin content. The purity of the NBN product as measured by SDS-PAGE and SEC was greater than 95%. The NBN product migrated under non-reducing conditions as a dimer, consistent with its predicted structure. The endotoxin content of the material is routinely less than 1 EU/mg. The specific activity of the NBN in the KIRA ELISA is approximately 10 nM. The product was formulated at 1 mg/mL in PBS pH 6.5. The material can be supplied as a frozen liquid, which is stored at -70°C.

Similar expression systems have also been constructed for human NBN. From these constructs, human NBN has been expressed in *E. coli*.

#### B. Expression in Mammalian Cells

**Construction of plasmid pJC070.14** In order to express the neublastin cDNA in Chinese hamster ovary cells, a cDNA fragment encoding the prepro form of human neublastin was inserted into the mammalian expression vector pEAG347 to generate plasmid pJC070.14. pEAG347 contains tandem SV40 early and adenovirus major late promoters (derived from plasmid pAD2beta; Norton and Coffin, Mol. Cell. Biol. 5: 281 (1985)), a unique NotI cloning

site, followed by SV40 late transcription termination and polyA signals (derived from plasmid pCMVbeta; MacGregor and Caskey, Nucl. Acids. Res. 17: 2365 (1989)). In addition, pEAG347 contains a pUC19-derived plasmid backbone and a pSV2dhfr-derived dhfr for MTX selection and amplification in transfected CHO cells.

5 Plasmid pJC070.14 was generated in two steps. First, a fragment encoding the prepro form of human neublastin was isolated from plasmid pUbi1Z-NBN using the polymerase chain reaction with oligonucleotides KD2-824 5'AAGGAAAAAA CGGGCCGCCA TGGAACTTGG ACTTGGAGG3' (SEQ ID NO:9), KD2-825 5'TTTTTTCCTT GGCGGCCGCT CAGCCCAGGC AGCCGCAGG3' (SEQ ID NO:10) and PFU polymerase.

10 The fragment was cloned into the Srf-1 site of pPCR-Script Amp SK(+) to generate the plasmid pJC069. In the second step, a partial Not-1 digest was performed on plasmid pJC069 to generate a 685bp fragment (containing the neublastin gene) which was cloned into the Not-1 site of plasmid pEAG347 to generate plasmid pJC070.14. Transcription of the neublastin gene in plasmid pJC070.14 is controlled by the adenovirus major late promoter.

15 **Generation of CHO cell lines expressing Neublastin.** 200 µg of pJC070.14 was linearized by digestion with the restriction endonuclease Mlu-1. The DNA was extracted with phenol: chloroform:isoamyl alcohol (25:24:1) and ethanol precipitated. The linearized DNA was resuspended in 20mM Hepes pH7.05, 137mM NaCl, 5mM KCl, 0.7mM Na<sub>2</sub>HPO<sub>4</sub>, 6mM dextrose (HEBS) and introduced into ~4E7 CHO dukx B1(*dhfr*-) cells (p23) by electroporation 20 (280V and 960 µF). Following electroporation, the cells were returned to culture in α+ Modified Eagle's Medium (MEM) supplemented with 10% fetal bovine serum (FBS) for two days. The cells were then trypsinized and replated in 100 mm dishes (100,000 cells/plate) in α-MEM (lacking ribo- and deoxyribonucleosides), supplemented with 10% dialyzed FBS, for five days. The cells were subsequently split at a density of 100,000 cells/100mm plate, and 25 selected in 200nM methotrexate. Resistant colonies were picked and scaled up to 6 well plates; conditioned media from each clone was screened using a specific assay for neublastin described below. The twelve clones expressing the highest level of neublastin were scaled up to T162 flasks and subsequently reassayed. These CHO cell lines produced neublastin in the range of 25 to 50 ng/ml/day.

30 **Ternary complex assay for neublastin.** The presence of neublastin was assessed in the media of CHO cell line supernatants using a modified form of a ternary complex assay described by Sanicola et al. (Proc Natl Acad Sci USA 94: 6238 (1997).

Similar mammalian expression constructs have been made and similar studies have been performed for both human NBN and rat NBN. *In vivo* testing of NBN activity in rats have been performed. Rat studies almost exclusively were performed with rat NBN.

#### **EXAMPLE 2: Efficacy of Full Length Neublastin in a Nerve Ligation Animal Model of**

##### **5 Neuropathic Pain – Prevention of Neuropathic Pain**

The preventive effect of neublastin on tactile allodynia and thermal hyperalgesia was studied in the Chung L5/L6 spinal nerve ligation (“SNL”) model (Kim and Chung (1992), Pain 50: 355-363. Sprague-Dawley male rats (250-300 g) were divided into four groups. One group of rats (n=7) received a sham operation, and were administered vehicle by subcutaneous injection. A second group of rats (n=7) received a sham operation and were administered rat Neublastin (1mg/kg) by subcutaneous injection. A third group of rats (n=7) received the spinal nerve ligation, and were administered vehicle by subcutaneous injection. A fourth group of rats (n=7) received the spinal nerve ligation, and were administered rat neublastin (1 mg/kg) by subcutaneous injection. The vehicle consisted of 5mM phosphate and 150mM sodium chloride at pH 6.5. Neublastin or vehicle was injected 30 minutes before the spinal nerve ligation or sham operation, and then on days 2, 4, 7, 9, 11 and 14 following the ligation or operation (post-SNL). The Von Frey (Chaplan et al. (1994), J. Neurosci. Meth. 53: 55-63) and Hargreave’s (Hargreaves et al. (1988), Pain 32: 77-88) behavioral tests were used to monitor tactile and thermal responses, respectively. These pain responses were monitored prior to the spinal nerve ligation or sham operation to establish baseline responses, and then daily for two weeks following the operation.

The results are depicted in FIGS. 1 and 2 as averages ± standard errors of the mean.

Subcutaneous administration of neublastin (as denoted by downward arrows in FIGS. 1 and 2) led to nearly complete normalization of both types of neuropathic pain (tactile, FIG. 1 and thermal, FIG. 2) in rats with spinal nerve ligation. In sham operated rats, subcutaneous administration of neublastin did not significantly alter tactile (FIG. 1) or thermal sensitivity (FIG. 2). In spinal nerve ligated rats, the effect of neublastin on thermal sensitivity first became evident 3 days after the initiation of neublastin administration, whereas the effect on tactile allodynia first became evident slightly later, at 4-5 days after the initiation of neublastin administration. The effect of neublastin on thermal sensitivity reached a plateau approximately 7-8 days after the initiation of neublastin administration whereas the effect on tactile allodynia

reached a plateau on approximately 10-11 days after the initiation of neublastin administration. The effects of neublastin did not diminish during the 2-3 day interval between administrations. In fact, there was substantial normalization of both pain behaviors between the administrations of neublastin on days 4 and 7, as measured on days 5 and 6. Following the administration of 5 neublastin on day 11, the extant maximal normalization of both pain behaviors remained constant, suggesting that the normalization effect of neublastin on neuropathic pain is maintained for at least 3 days.

### **EXAMPLE 3: Treatment of Neuropathy With a Truncated Neublastin Polypeptide**

The preventive effect of a polypeptide containing the carboxy terminal 102 amino acids 10 of mature rat neublastin in treating tactile allodynia and thermal hyperalgesia, two peripheral neuropathic conditions, is demonstrated in a Chung L5/L6 spinal nerve ligation (“SNL”) model.

Sprague-Daley male rats (approximately 250-300 grams) are divided into four groups. One group of rats (n=6) receive a sham operation and are administered vehicle by subcutaneous 15 injection. A second group of rats (n=6) receive a sham operation and are administered truncated neublastin (1 mg/kg) by subcutaneous injection. A third group of rats (n =6) receive a spinal nerve ligation and are administered vehicle by subcutaneous ligation. A fourth group (n=6) receives the spinal nerve ligation, and are administered truncated neublastin (1 mg/kg) by subcutaneous injection. The vehicle includes 5 mM phosphate and 150 mM sodium chloride at 20 pH 6.5. Truncated neublastin or vehicle is administered on days 0, 2, 4, 7, 9, 11 and 14. On day 0, truncated neublastin is administered 30 minutes before the spinal nerve ligation or sham operation. Pain responses are determined using behavioral tests as described in Chaplan et al. (1994), *J. Neurosci. Meth.* 53:55-63 and Hargreaves et al. (1988), *Pain* 32:77-88. These tests monitor tactile and thermal responses, respectively. The pain responses are monitored prior to 25 the spinal nerve ligation or sham operation to establish baseline responses. Pain responses are then monitored daily for two weeks following the operation.

Subcutaneous administration of truncated neublastin is expected to lead to normalization of both types of neuropathic pain in rats with spinal nerve ligation. In sham operated rats, subcutaneous administration of truncated neublastin is not expected to 30 significantly alter tactile or thermal sensitivity. The effect of neublastin on thermal sensitivity

is predicted to become evident about 3 days after the administration of neublastin, whereas the effect on tactile allodynia is expected to first become evident slightly later.

**EXAMPLE 4: Neublastin Efficacy in a Nerve Ligation Animal Model of Neuropathic Pain – Reversal of Neuropathic Pain**

5       The reversal effect of neublastin on tactile allodynia and thermal hyperalgesia was studied in the Chung L5/L6 spinal nerve ligation (“SNL”) model. Sprague-Dawley male rats (270 - 275g) were divided into four groups. One group of rats (n=8) received a sham operation, and were administered vehicle by subcutaneous injection. A second group of rats (n=8) received a sham operation and were administered rat neublastin (1mg/kg) by 10 subcutaneous injection. A third group of rats (n=8) received the spinal nerve ligation, and were administered vehicle by subcutaneous injection. A fourth group of rats (n=8) received the spinal nerve ligation, and were administered rat neublastin (1 mg/kg) by subcutaneous injection. The vehicle consisted of 5mM phosphate and 150mM sodium chloride at pH 6.5. The Von Frey (Chaplan et al. (1994), *J. Neurosci. Meth.* 53: 55-63) and Hargreave’s 15 (Hargreaves et al. (1988), *Pain* 32: 77-88) behavioral tests were used to monitor tactile and thermal responses, respectively. These pain responses were monitored prior to the spinal nerve ligation or sham operation to establish baseline responses, and then daily for 2 weeks following the operation. Neublastin or vehicle was injected 60 minutes before behavioral testing on days 3, 5, 7, 10, 12 and 14 following the ligation or operation (post-SNL).

20       The results are depicted in FIGS. 3 and 4 as averages ± standard errors of the mean. Both types of neuropathic pain behavior (tactile allodynia shown in FIG. 3, and thermal hyperalgesia shown in FIG. 4) developed fully by day 3, as expected. Subcutaneous administration of neublastin (as denoted by downward arrows in FIGS. 3 and 4) led to nearly complete reversal of both types of neuropathic pain (tactile in FIG. 3 and thermal in FIG. 4) in 25 rats with spinal nerve ligation, so that tactile and thermal responses were normalized. In sham operated rats, subcutaneous administration of neublastin did not significantly alter tactile (FIG. 3) or thermal (FIG. 4) sensitivity. In rats with spinal nerve ligation, the effect of neublastin on thermal sensitivity and tactile allodynia first became evident 2 to 3 days after the initiation of neublastin administration. The effect of neublastin on thermal sensitivity and tactile allodynia 30 reached a plateau approximately 7-8 days after the initiation of neublastin administration. The effects of neublastin did not diminish during the 2 to 3 day interval between administrations.

In fact, there was substantial normalization of both pain behaviors between the administrations of neublastin on days 3, 5, 7 and 10.

**EXAMPLE 5: Neublastin Efficacy in a Streptozotocin Animal Model of Neuropathic Pain – Prevention of Loss of Pain Sensitivity**

5       The preventive effect of neublastin on loss of thermal sensitivity (thermal hypoalgesia) was studied in the streptozotocin (“STZ”) model of diabetic neuropathy. Sprague-Dawley female rats (250 - 275g) were divided into 4 groups, each comprised of 10 animals. One group of rats did not receive STZ; these rats received vehicle by subcutaneous injection. Three groups of rats received 1 injection of STZ (50 mg/kg in sterile saline) and were subsequently  
10 confirmed to be hyperglycemic by spectrophotometric assay of blood samples. Of the 3 groups of hyperglycemic rats, 1 group received vehicle by subcutaneous injection, a second group was administered rat neublastin (0.1mg/kg) by subcutaneous injection, and a third group of rats was administered rat neublastin (1mg/kg) by subcutaneous injection. The vehicle consisted of 5mM phosphate and 150mM sodium chloride at pH 6.5. Neublastin or vehicle was  
15 administered 3 times per week (Monday, Wednesday, Friday schedule) for 8 weeks, and was initiated at the time of STZ induction of hyperglycemia. Thermal response latencies were assessed after 8 weeks as described in Calcutt et al. (2000), Anesthesiology 93: 1271-1278. In brief, a radiant heat source was applied to the plantar surface of the paw so that the surface temperature increased from 30 °C to 38.5°C in 20 seconds, and the time latency between  
20 initiation of heating and paw withdrawal was measured to assess thermal response latency. An increase in paw withdrawal latency indicates a loss of thermal sensitivity (thermal hypoalgesia).

The results are depicted in FIG. 5 as averages ± standard errors of the mean. As expected at 8 weeks post-STZ, the paw withdrawal latency increased in vehicle treated STZ rats (STZ vehicle) compared to normal rats, indicating that thermal hypoalgesia had been induced by the STZ injection. Administration of neublastin prevented the increase in thermal response latency in hyperglycemic (STZ) rats. Both doses of neublastin (1 mg/kg and 0.1 mg/kg) nearly completely normalized thermal sensitivity after 8 weeks of administration at 3 times per week. These results demonstrate that neublastin prevents thermal hypoalgesia, the  
30 loss of thermal sensitivity that occurs in the STZ rat model of diabetic neuropathy.

**EXAMPLE 6: Prevention of Thermal Hypoalgesia, and Prevention and Reversal of Thermal Hyperalgesia by Neublastin in Streptozotocin Rats.**

Rat NBN113 was prepared in *E. coli* as described in Example 1. The preventive effect of neublastin on loss of thermal sensitivity (thermal hypoalgesia), and prevention and reversal by neublastin of increased thermal sensitivity (thermal hyperalgesia) was studied in the streptozotocin (“STZ”) rat model of diabetic neuropathy, as described in Example 5. Dosage studies described in Example 5 were confirmed and extended upon. Results are shown in FIG. 6A and FIG. 6B.

The results in FIG. 6A and FIG. 6B are depicted as averages ± standard errors of the mean. As expected at 4 weeks post-STZ, the paw withdrawal latency decreased in vehicle-treated STZ rats, as compared to normal rats, indicating that thermal hyperalgesia had been induced by the STZ injection. All doses of subcutaneous neublastin (0.03 mg/kg and 0.1 mg/kg) prevented thermal hyperalgesia in STZ rats after 4 weeks of administration at 3 times per week, as shown in FIG. 6A. All doses of subcutaneous neublastin (0.03 mg/kg and 0.1 mg/kg) prevented thermal hypoalgesia in STZ rats after 8 weeks of administration at 3 times per week, as shown in FIG. 6B. In addition, as shown in FIG. 6B, subcutaneous neublastin (0.1 mg/kg) administered during the second 4 wks of the 8 week treatment study (veh; 0.1 mg/kg NBN) not only reversed the thermal hyperalgesia that was apparent at 4 weeks post STZ treatment, but also prevented thermal hypoalgesia at 8 weeks from developing in STZ rats. These results demonstrate that neublastin prevents and reverses thermal hyperalgesia in the STZ rat model of diabetic neuropathy, and that neublastin prevents the loss of thermal sensitivity (thermal hypoalgesia) that occurs in the STZ rat model of diabetic neuropathy.

**EXAMPLE 7: Neublastin Efficacy in a Nerve Ligation Animal Model of Neuropathic Pain - Reversal of Neuropathic Pain is Dose Dependent.**

Rat NBN113 was prepared in *E. coli* as described in Example 1. Analysis of dose-dependent reversal by NBN113 of tactile allodynia and thermal hyperalgesia was performed in rats using the Chung L5/L6 spinal nerve ligation (“SNL”) animal model, as described in Example 4, with NBN doses of 0.03 mg/kg, 0.1 mg/kg, 0.6 mg/kg and 2 mg/kg. Experimental results shown in FIGS 3 and 4 were confirmed and expanded upon. Results are shown in FIG. 7 and FIG. 8.

The results in FIGS. 7 and 8 are depicted as averages  $\pm$  standard errors of the mean. BL indicates baseline responses. Both types of neuropathic pain behavior (tactile allodynia shown in FIG. 7, and thermal hyperalgesia shown in FIG. 8) developed fully by day 2, as expected. Subcutaneous administration of 2 mg/kg neublastin (NBN) 3 times per week (as denoted by the 5 arrows) led to nearly complete reversal of both types of neuropathic pain (tactile in FIG. 7 and thermal in FIG. 8) in rats with spinal nerve ligation, so that tactile and thermal responses were normalized. As shown in FIG. 7, neublastin reversal of spinal nerve ligation-induced tactile allodynia was dose-dependent. Neublastin (NBN) dosing at 0.1 mg/kg s.c. or 0.6 mg/kg s.c. partially reversed tactile allodynia after 9 (as well as 11) days of dosing three times per week, 10 whereas NBN at 2 mg/kg s.c. significantly reversed tactile allodynia after 7 (as well as 9 and 11) days of dosing three times per week, with nearly complete reversal of tactile allodynia after 9 and 11 days of dosing three times per week. Moreover, the mean reversal of spinal nerve ligation-induced tactile allodynia on day 14 post-SNL was greater with increasing 15 subcutaneous doses of neublastin from 0.1 mg/kg to 0.6 mg/kg to 2 mg/kg. Neublastin (NBN) at 0.03 mg/kg s.c. did not significantly reverse spinal nerve ligation-induced tactile allodynia during 11 days of dosing at three times per week.

As depicted in FIG. 8, Neublastin (NBN) reversal of spinal nerve ligation (SNL) - induced thermal hyperalgesia was also dose-dependent. NBN dosing at 0.1 mg/kg significantly reversed thermal hyperalgesia after 9 (as well as 11) days of dosing three times per week, NBN 20 at 0.6 mg/kg significantly reversed thermal hyperalgesia after 7 (as well as 9 and 11) days of dosing three times per week, and NBN at 2 mg/kg significantly reversed thermal hyperalgesia after 4 (as well as 7, 9 and 11) days of dosing three times per week. Moreover, the mean reversal of spinal nerve ligation-induced thermal hyperalgesia on day 14 post-SNL was greater with increasing subcutaneous doses of neublastin from 0.1 mg/kg to 0.6 mg/kg to 2 mg/kg. 25 NBN at 0.03 mg/kg s.c. did not significantly reverse spinal nerve ligation-induced thermal hyperalgesia during 11 days of dosing at three times per week.

## EQUIVALENTS

Although particular embodiments have been disclosed herein in detail, this has been done by way of example for purposes of illustration only, and is not intended to be limiting 30 with respect to the scope of the appended claims which follow. In particular, various

substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the claims.

## CLAIMS

### WHAT IS CLAIMED IS:

1. A method for treating neuropathic pain in a subject, the method comprising administering to the subject a formulation comprising a neublastin polypeptide at a dosage of between 1  $\mu\text{g}/\text{kg}$  to 30,000  $\mu\text{g}/\text{kg}$  body weight of the subject, per dose.
2. The method of claim 1 wherein the neuropathic pain is associated with post-herpetic neuralgia, diabetic neuropathy, or sciatica.
3. A method for treating tactile allodynia in a subject, the method comprising administering to the subject a neublastin polypeptide at a dosage of between 10  $\mu\text{g}/\text{kg}$  to 30,000  $\mu\text{g}/\text{kg}$  body weight of the subject per dose.
4. The method of claim 1 or 3, wherein the neublastin polypeptide is administered using a delivery system selected from the group consisting of intravenous delivery, intramuscular delivery, intrapulmonary delivery, subcutaneous delivery, and intraperitoneal delivery.
5. The method of claim 1 or 3, wherein the neublastin polypeptide is administered via intramuscular delivery or subcutaneous delivery.
6. The method of claim 1 or 3 wherein the dosage is between 10  $\mu\text{g}/\text{kg}$  to 10,000  $\mu\text{g}/\text{kg}$  body weight of the subject, per dose.
7. The method of claim 1 or 3 wherein the dosage is between 25  $\mu\text{g}/\text{kg}$  to 3,000  $\mu\text{g}/\text{kg}$  body weight of the subject, per dose.
8. The method of claim 1 or 3, wherein said the amino acid sequence of said neublastin polypeptide comprises a polypeptide selected from the group consisting of:
  - (a) at least one polypeptide comprising AA<sub>-80</sub>-AA<sub>140</sub> of SEQ ID NO:2, AA<sub>-41</sub>-AA<sub>140</sub> of SEQ ID NO:2, AA<sub>1</sub>-AA<sub>140</sub> of SEQ ID NO:2, AA<sub>25</sub>-AA<sub>140</sub> of SEQ ID NO:2, AA<sub>28</sub>-AA<sub>140</sub> of

SEQ ID NO:2, AA<sub>80</sub>-AA<sub>144</sub> of SEQ ID NO:4, AA<sub>1</sub>-AA<sub>144</sub> of SEQ ID NO:4, AA<sub>1</sub>-AA<sub>224</sub> of SEQ ID NO:5, or AA<sub>81</sub>-AA<sub>224</sub> of SEQ ID NO:5;

(b) at least one polypeptide comprising the C-terminal sequence set forth in either AA<sub>107</sub>-AA<sub>140</sub> of SEQ ID NO:2 or AA<sub>76</sub>-AA<sub>140</sub> of SEQ ID NO:2, and which retain the seven Cys residues characteristic of the GDNF family and of the TGF- $\beta$  super family;

(c) at least one polypeptide comprising SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26 or SEQ ID NO:27; and

(d) at least one polypeptide sequence that has greater than 70% amino acid homology to any one of the sequences in (a) - (c) above.

9. The method of claim 1 or 3, wherein the neublastin polypeptide is administered in a timed-release composition.

10. The method of claim 1 or 3 wherein the neublastin polypeptide is modified with a derivative moiety to have an extended residence time and/or increased concentration in body fluids.

11. The method of claim 10 wherein the derivative moiety is a polyethylene glycol moiety.

12. The method of claim 10 wherein the derivative moiety is selected from the group consisting of aliphatic esters, amides, N-acyl-derivatives, or O-acyl derivatives.

13. A method for treating neuropathic pain in a subject comprising:

a) administering to the subject an effective amount of a neublastin polypeptide; and

b) administering to the subject an effective amount of an analgesia-inducing compound selected from the group consisting of opioids, anti-arrhythmics, topical analgesics, local anaesthetics, anticonvulsants, antidepressants, corticosteroids and NSAIDS.

14. The method of claim 13 wherein the neuropathic pain is associated with post-herpetic neuralgia, diabetic neuropathy, or sciatica.

15. A method for treating tactile allodynia in a subject, the method comprising:

a) administering to the subject an effective amount of a neublastin polypeptide; and

b) administering to the subject an effective amount of an analgesia-inducing compound selected from the group consisting of opioids, anti-arrhythmics, topical analgesics, local anaesthetics, anticonvulsants, antidepressants, corticosteroids and NSAIDS.

16. The method of claim 13 or 15 wherein the analgesia-inducing compound in (b) is an anticonvulsant.

17. The method of claim 13 or 15 wherein the analgesia-inducing compound in (b) is gabapentin (1-(aminomethyl)cyclohexane acetic acid) or pregabalin (S-(+)-4-amino-3-(2-methylpropyl)butanoic acid).

18. The method of claim 13 or 15, wherein the neublastin polypeptide is administered using a delivery system selected from the group consisting of intravenous delivery, intramuscular delivery, intrapulmonary delivery, subcutaneous delivery, and intraperitoneal delivery.

19. The method of claim 13 or 15, wherein the neublastin polypeptide is administered via intramuscular delivery or subcutaneous delivery.

20. The method of claim 13 or 15 wherein the dosage of the neublastin polypeptide is between 10 µg/kg to 10,000 µg/kg body weight of the subject, per dose.

21. The method of claim 13 or 15 wherein the dosage of the neublastin polypeptide is between 25 µg/kg to 3,000 µg/kg body weight of the subject, per dose.

22. The method of claim 13 or 15, wherein said the amino acid sequence of said neublastin polypeptide comprises a polypeptide selected from the group consisting of:

(a) at least one polypeptide comprising AA<sub>80</sub>-AA<sub>140</sub> of SEQ ID NO:2, AA<sub>41</sub>-AA<sub>140</sub> of SEQ ID NO:2, AA<sub>1</sub>-AA<sub>140</sub> of SEQ ID NO:2, AA<sub>25</sub>-AA<sub>140</sub> of SEQ ID NO:2, AA<sub>28</sub>-AA<sub>140</sub> of SEQ ID NO:2, AA<sub>80</sub>-AA<sub>144</sub> of SEQ ID NO:4, AA<sub>1</sub>-AA<sub>144</sub> of SEQ ID NO:4, AA<sub>1</sub>-AA<sub>224</sub> of SEQ ID NO:5, or AA<sub>81</sub>-AA<sub>224</sub> of SEQ ID NO:5;

(b) at least one polypeptide comprising the C-terminal sequence set forth in either AA<sub>107</sub>-AA<sub>140</sub> of SEQ ID NO:2 or AA<sub>76</sub>-AA<sub>140</sub> of SEQ ID NO:2, and which retain the seven Cys residues characteristic of the GDNF family and of the TGF-beta super family;

(c) at least one polypeptide comprising SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26 or SEQ ID NO:27; and

(d) at least one polypeptide sequence that has greater than 70% amino acid homology to the sequences in (a) - (c) above.

23. The method of claim 13 or 15, wherein the neublastin polypeptide is administered in a timed-release composition.

24. The method of claim 13 or 15 wherein the neublastin polypeptide is modified with a derivative moiety to have an extended residence time and/or increased concentration in body fluids.

25. The method of claim 24 wherein the derivative moiety is a polyethylene glycol moiety.

26. The method of claim 24 wherein the derivative moiety is selected from the group consisting of aliphatic esters, amides, N-acyl-derivatives, or O-acyl derivatives.

27. The method of claims 1 or 13, wherein said neuropathic pain is associated with infection of said subject by a virus.

28. The method of claim 27, wherein said virus is selected from the group consisting of a herpes virus, a human immunodeficiency virus (HIV), a papilloma virus.

29. The method of claims 1 or 13, wherein said neuropathic pain is neuropathic pain associated with administration of a therapeutic agent.

30. The method of claim 29, wherein said therapeutic agent is an anti-cancer agent.

31. The method of claim 30 wherein the anti-cancer agent is selected from the group consisting of taxol, taxotere, cisplatin, nocodazole, vincristine, vindesine and vinblastine.

32. The method of claim 29, wherein said therapeutic agent is an anti-viral agent.

33. The method of claim 32, wherein said anti-viral agent is selected from the group consisting of ddI, DDC, d4T, foscarnet, dapsone, metronidazole, and isoniazid.

34. The method of claim 1 or 13, wherein said neuropathic pain is due to injury associated with trauma.

35. The method of claim 1 or 13, wherein said neuropathic pain is allodynia.

36. The method of claim 1 or 13, wherein said neuropathic pain is hyperalgesic pain.

37. The method of claim 36 wherein the hyperalgesic pain is thermal hyperalgesia.

38. The method of claim 1 or 13, wherein said neuropathic pain is phantom pain.

39. The method of claim 1 or 13, wherein the neuropathic pain is associated with hereditary neuropathy (including but not limited to Friedreich ataxia, familial amyloid polyneuropathy, Tangier disease, Fabry disease), metabolic disorders (including but not limited to renal insufficiency and hypothyroidism), vitamin deficiencies (including but not limited to vitamin B12 deficiency, vitamin B6 deficiency, and vitamin E deficiency), toxic and iatrogenic neuropathies (including but not limited to alcoholism, vitamin B6 intoxication, hexacarbon intoxication, amiodarone, chloramphenicol, disulfiram, isoniazide, gold, lithium, metronidazole, misonidazole, nitrofurantoin), infectious neuropathies (including but not limited to leprosy, Lyme disease), auto-immune neuropathies (including but not limited to Guillain-Barre syndrome, chronic inflammatory de-myelinating polyneuropathy, monoclonal gammopathy of undetermined significance and polyneuropathy), trigeminal neuralgia, entrapment syndromes (including but not limited to Carpel tunnel), post-traumatic neuralgia, phantom limb pain, multiple sclerosis pain, complex regional pain syndromes (including but not limited to reflex sympathetic dystrophy, causalgia), neoplasia, vasculitic/angiopathic neuropathy and idiopathic neuropathy.

40. A method for reducing the loss of pain sensitivity in a subject afflicted with a neuropathy, the method comprising administering a formulation comprising a neublastin polypeptide at a dosage of between 1  $\mu\text{g}/\text{kg}$  to 30,000  $\mu\text{g}/\text{kg}$  body weight of the subject, per dose.

41. The method of claim 40 wherein the neuropathy is diabetic neuropathy.

42. The method of claim 40 wherein the loss of pain sensitivity is a loss in thermal pain sensitivity.

43. The method of claim 40, wherein the neublastin polypeptide is administered using a delivery system selected from the group consisting of intravenous delivery, intramuscular delivery, intrapulmonary delivery, subcutaneous delivery, and intraperitoneal delivery.

44. The method of claim 40, wherein the neublastin polypeptide is administered via intramuscular delivery or subcutaneous delivery.

45. The method of claim 40 wherein the dosage is between 10 µg/kg to 10,000 µg/kg body weight of the subject, per dose.

46. The method of claim 40 wherein the dosage is between 25 µg/kg to 3,000 µg/kg body weight of the subject, per dose.

47. The method of claim 40, wherein said the amino acid sequence of said neublastin polypeptide comprises a polypeptide selected from the group consisting of:

(a) at least one polypeptide comprising AA<sub>80</sub>-AA<sub>140</sub> of SEQ ID NO:2, AA<sub>41</sub>-AA<sub>140</sub> of SEQ ID NO:2, AA<sub>1</sub>-AA<sub>140</sub> of SEQ ID NO:2, AA<sub>25</sub>-AA<sub>140</sub> of SEQ ID NO:2, AA<sub>28</sub>-AA<sub>140</sub> of SEQ ID NO:2, AA<sub>80</sub>-AA<sub>144</sub> of SEQ ID NO:4, AA<sub>1</sub>-AA<sub>144</sub> of SEQ ID NO:4, AA<sub>1</sub>-AA<sub>224</sub> of SEQ ID NO:5, or AA<sub>81</sub>-AA<sub>224</sub> of SEQ ID NO:5;

(b) at least one polypeptide comprising the C-terminal sequence set forth in either AA<sub>107</sub>-AA<sub>140</sub> of SEQ ID NO:2 or AA<sub>76</sub>-AA<sub>140</sub> of SEQ ID NO:2, and which retain the seven Cys residues characteristic of the GDNF family and of the TGF-beta super family;

(c) at least one polypeptide comprising SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26 or SEQ ID NO:27; and

(d) at least one polypeptide sequence that has greater than 70% amino acid homology to the sequences in (a) - (c) above.

48. The method of claim 40, wherein the neublastin polypeptide is administered in a timed-release composition.

49. The method of claim 40 wherein the neublastin polypeptide is modified with a derivative moiety to have an extended residence time and/or increased concentration in body fluids.

50. The method of claim 40 wherein the derivative moiety is a polyethylene glycol moiety.

51. The method of claim 40 wherein the derivative moiety is selected from the group consisting of aliphatic esters, amides, N-acyl-derivatives, or O-acyl derivatives.

52. A method for treating, preventing or delaying neuropathic pain in a subject, the method comprising administering to the subject a formulation comprising a neublastin polypeptide at a dosage of between 1 µg/kg to 30,000 µg/kg body weight of the subject, per dose, wherein administering of neublastin polypeptide is prophylactic.

53. The method of claim 52, wherein the neublastin polypeptide is administered using a delivery system selected from the group consisting of: intravenous delivery, intramuscular delivery, intrapulmonary delivery, subcutaneous delivery, and intraperitoneal delivery.

54. A method for treating diabetic neuropathy in a subject, the method comprising administering to the subject a formulation comprising a neublastin polypeptide at a dosage of between 1 µg/kg to 30,000 µg/kg body weight of the subject, per dose.

55. The method of claim 52 or 54, wherein the neublastin polypeptide is administered using a delivery system selected from the group consisting of intravenous delivery, intramuscular delivery, intrapulmonary delivery, subcutaneous delivery, and intraperitoneal delivery.

56. The method of claim 52 or 54, wherein said the amino acid sequence of said neublastin polypeptide comprises a polypeptide selected from the group consisting of:


(a) at least one polypeptide comprising AA<sub>80</sub>-AA<sub>140</sub> of SEQ ID NO:2, AA<sub>41</sub>-AA<sub>140</sub> of SEQ ID NO:2, AA<sub>1</sub>-AA<sub>140</sub> of SEQ ID NO:2, AA<sub>25</sub>-AA<sub>140</sub> of SEQ ID NO:2, AA<sub>28</sub>-AA<sub>140</sub> of SEQ ID NO:2, AA<sub>80</sub>-AA<sub>144</sub> of SEQ ID NO:4, AA<sub>1</sub>-AA<sub>144</sub> of SEQ ID NO:4, AA<sub>1</sub>-AA<sub>224</sub> of SEQ ID NO:5, or AA<sub>81</sub>-AA<sub>224</sub> of SEQ ID NO:5;

(b) at least one polypeptide comprising the C-terminal sequence set forth in either AA<sub>107</sub>-AA<sub>140</sub> of SEQ ID NO:2 or AA<sub>76</sub>-AA<sub>140</sub> of SEQ ID NO:2, and which retain the seven Cys residues characteristic of the GDNF family and of the TGF-β super family;

(c) at least one polypeptide comprising SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26 or SEQ ID NO:27; and


(d) at least one polypeptide sequence that has greater than 70% amino acid homology to any one of the sequences in (a) - (c) above.

**Figure 1: Prevention of Tactile Allodynia by Neublastin in Rats With Spinal Nerve Ligation (SNL)**




2/8

**Figure 2: Prevention of Thermal Hyperalgesia by Neublastin in Rats With Spinal Nerve Ligation (SNL)**




3/8




4/8

**Figure 4: Reversal of Thermal Hyperalgesia by Neublastin in Rats With Spinal Nerve Ligation (SNL)**




5/8

**Figure 5: Prevention of Thermal Hypoalgesia by Neublastin in Streptozotocin (STZ) Rats**




6/8

**Figure 6: Prevention of Thermal Hypoalgesia, & Prevention & Reversal of Thermal Hyperalgesia by Neublastin in Streptozotocin (STZ) Rats**




7/8

**Figure 7: NBN Reversal of Tactile Allodynia is Dose-Dependent**



8/8

**Figure 8: NBN Reversal of Thermal Hyperalgesia is Dose-Dependent**



## SEQUENCE LISTING

<110> Biogen, Inc.  
Sah, Dinah Wen-Yee

<120> Treatment Using Neublastin Polypeptides

<130> 00689-507 (A118) utility

<140> Filed Herewith

<141> 2002-02-28

<150> USSN 06/287,554  
<151> 2001-03-28

<160> 27

<170> PatentIn Ver. 2.1

<210> 1  
<211> 861  
<212> DNA  
<213> Homo sapiens

<220>  
<221> CDS  
<222> (58)..(717)

<220>  
<221> 5'UTR  
<222> (1)..(57)

<220>  
<221> 3'UTR  
<222> (718)..(861)

<220>  
<221> sig\_peptide  
<222> (58)..(174)

<220>  
<221> mat\_peptide  
<222> (298)..(717)

<220>  
<221> mat\_peptide  
<222> (370)..(717)

<220>  
<221> mat\_peptide  
<222> (379)..(717)

<220>  
<221> misc\_structure  
<222> (661)..(663)  
<223> CARBOHYD: glycosylated asparagine at Asn122

<220>  
<221> misc\_structure  
<222> (424)..(621)  
<223> DISULFID: Gly43-Gly108 disulfide bridge

<220>

```

<221> misc_structure
<222> (505)..(705)
<223> DISULFID: Gly70-Gly136 disulfide bridge

<220>
<221> misc_structure
<222> (517)..(711)
<223> DISULFID: Gly74-Gly138 disulfide bridge

<220>
<221> misc_structure
<222> (616)..(618)
<223> DISULFID: Gly107-Gly107 interchain disulfide
bridge

<400> 1
aggagggtgg gggAACAGCT caacaatggc tGATGGCGC tcctgggtttt gatAGAG      57
atg gaa ctt gga ctt gga ggc ctc tcc acg ctg tcc cac tgc ccc tgg      105
Met Glu Leu Gly Leu Gly Gly Ser Thr Leu Ser His Cys Pro Trp
-80          -75           -70           -65

cct agg cgg cag cct gcc ctg tgg ccc acc ctg gcc gct ctg gct ctg      153
Pro Arg Arg Gln Pro Ala Leu Trp Pro Thr Leu Ala Ala Leu Ala Leu
-60          -55           -50

ctg agc agc gtc gca gag gcc tcc ctg ggc tcc gcg ccc cgc agc cct      201
Leu Ser Ser Val Ala Glu Ala Ser Leu Gly Ser Ala Pro Arg Ser Pro
-45          -40           -35

gcc ccc cgc gaa ggc ccc ccg cct gtc ctg gcg tcc ccc gcc ggc cac      249
Ala Pro Arg Glu Gly Pro Pro Val Leu Ala Ser Pro Ala Gly His
-30          -25           -20

ctg ccg ggg gga cgc acg gcc cgc tgg tgc agt gga aga gcc cgg cgg      297
Leu Pro Gly Gly Arg Thr Ala Arg Trp Cys Ser Gly Arg Ala Arg Arg
-15          -10           -5            -1

ccg ccg ccg cag cct tct cgg ccc gcg ccc ccg ccg cct gca ccc cca      345
Pro Pro Pro Gln Pro Ser Arg Pro Ala Pro Pro Pro Ala Pro Pro
1           5             10           15

tct gct ctt ccc cgc ggg ggc cgc gcg cgg gct ggg ggc ccg ggc      393
Ser Ala Leu Pro Arg Gly Gly Arg Ala Ala Arg Ala Gly Gly Pro Gly
20          25           30

agc cgc gct cgg gca gcg ggg gcg cgg ggc tgc cgc ctg cgc tcg cag      441
Ser Arg Ala Arg Ala Gly Ala Arg Gly Cys Arg Leu Arg Ser Gln
35          40           45

ctg gtg ccg gtg cgc gcg ctc ggc ctg ggc cac cgc tcc gac gag ctg      489
Leu Val Pro Val Arg Ala Leu Gly Leu Gly His Arg Ser Asp Glu Leu
50          55           60

gtg cgt ttc cgc ttc tgc agc ggc tcc tgc cgc cgc gcg cgc tct cca      537
Val Arg Phe Arg Phe Cys Ser Gly Ser Cys Arg Arg Ala Arg Ser Pro
65          70           75           80

cac gac ctc agc ctg gcc agc cta ctg ggc gcc ggg gcc ctg cga ccg      585
His Asp Leu Ser Leu Ala Ser Leu Leu Gly Ala Gly Ala Leu Arg Pro
85          90           95

ccc ccg ggc tcc cgg ccc gtc agc cag ccc tgc tgc cga ccc acg cgc      633
Pro Pro Gly Ser Arg Pro Val Ser Gln Pro Cys Cys Arg Pro Thr Arg

```

100	105	110	
tac gaa gcg gtc tcc ttc atg gac gtc aac agc acc tgg aga acc gtg Tyr Glu Ala Val Ser Phe Met Asp Val Asn Ser Thr Trp Arg Thr Val	115	120	681
125			
gac cgc ctc tcc gcc acc gcc tgc ggc tgc ctg ggc tgagggtctcg Asp Arg Leu Ser Ala Thr Ala Cys Gly Cys Leu Gly	130	135	727
140			
ctccagggct ttgcagactg gacccttacc ggtggcttt cctgcctggg accctccccgc 787			
agagtcccac tagccagcgg cctcagccag ggacgaaggc ctcaaagctg agaggcccct 847			
accggtgtgggt gatg 861			
<210> 2			
<211> 220			
<212> PRT			
<213> Homo sapiens			
<400> 2			
Met Glu Leu Gly Leu Gly Gly Leu Ser Thr Leu Ser His Cys Pro Trp -80 -75 -70 -65			
Pro Arg Arg Gln Pro Ala Leu Trp Pro Thr Leu Ala Ala Leu Ala Leu -60 -55 -50			
Leu Ser Ser Val Ala Glu Ala Ser Leu Gly Ser Ala Pro Arg Ser Pro -45 -40 -35			
Ala Pro Arg Glu Gly Pro Pro Val Leu Ala Ser Pro Ala Gly His -30 -25 -20			
Leu Pro Gly Gly Arg Thr Ala Arg Trp Cys Ser Gly Arg Ala Arg Arg -15 -10 -5 -1			
Pro Pro Pro Gln Pro Ser Arg Pro Ala Pro Pro Pro Pro Ala Pro Pro 1 5 10 15			
Ser Ala Leu Pro Arg Gly Arg Ala Ala Arg Ala Gly Gly Pro Gly 20 25 30			
Ser Arg Ala Arg Ala Ala Gly Ala Arg Gly Cys Arg Leu Arg Ser Gln 35 40 45			
Leu Val Pro Val Arg Ala Leu Gly Leu Gly His Arg Ser Asp Glu Leu 50 55 60			
Val Arg Phe Arg Phe Cys Ser Gly Ser Cys Arg Arg Ala Arg Ser Pro 65 70 75 80			
His Asp Leu Ser Leu Ala Ser Leu Leu Gly Ala Gly Ala Leu Arg Pro 85 90 95			
Pro Pro Gly Ser Arg Pro Val Ser Gln Pro Cys Cys Arg Pro Thr Arg 100 105 110			
Tyr Glu Ala Val Ser Phe Met Asp Val Asn Ser Thr Trp Arg Thr Val 115 120 125			
Asp Arg Leu Ser Ala Thr Ala Cys Gly Cys Leu Gly 130 135 140			

<210> 3  
<211> 2136  
<212> DNA  
<213> Murinae gen. sp.

<220>  
<221> CDS  
<222> (975) .. (1646)

<220>  
<221> 5'UTR  
<222> (1) .. (974)

<220>  
<221> 3'UTR  
<222> (1647) .. (2136)

<220>  
<221> sig\_peptide  
<222> (975) .. (1091)

<220>  
<221> mat\_peptide  
<222> (1215) .. (1646)

<220>  
<221> mat\_peptide  
<222> (1290) .. (1646)

<220>  
<221> mat\_peptide  
<222> (1299) .. (1646)

<400> 3  
gcggccgcga attcggcacg agggcgcttc gctgcagccc gcgatctcta ctctgcctcc 60  
tggggtcttc tccaaatgtc tagccccac ctagaggac ctagcctagc cagcggggac 120  
cggatccgga gggtgagcg gccaggtgag ccctgaaagg tggggcgaaa cggggcgct 180  
ctggggccca ccccggtatc tggtgacgcc ggggctggaa tttgacaccg gacggcggcg 240  
ggcaggaggc tgctgaggga tggagttggg ctggggccccc agatgcggcc cgccggctct 300  
gccagcaaca agtccctcg gccccagccc tcgctgcac tggggcttgg agccctgcac 360  
ccaagggcac agaccggctg ccaaggcccc acttttaact aaaagaggcg ctgccagggtg 420  
cacaactctg ggcatgatcc acttgagctt cggggaaaag cccagcactg gtcccaggag 480  
aggcgctag aaggacacgg accaggaccc ctttgtatg gagtgaacgc tgagcatgga 540  
gtggaaggaa ctcaagttac tactttctcc aaccaccctg gtaccttcag ccctgaagta 600  
cagagcagaa gggcttaga agacaggacc acagctgtgt gagtctcccc cctgaggcct 660  
tagacgatct ctgagctcag ctgagcttg tttgcccattc tggagaagtg agccattgtat 720  
tgaccttgtg gcatcgcaa ggaacaggac ctgccaagca cctaacadag agagcaaggt 780  
tctccatcgc agctaccgct gctgagttga ctctagctac tccaaacctcc tgggtcgctt 840

cgagagactg gagtggagg aggaataccc caaaggataa ctaactcatc tttcagtttg 900  
 caagctgccg caggaagagg gtggggaaac gggccacga aggctctga tggagcttc 960  
 tggagccgaa agct atg gaa ctg gga ctt gca gag cct act gca ttg tcc 1010  
     Met Glu Leu Gly Leu Ala Glu Pro Thr Ala Leu Ser  
     -80                  -75                  -70  
 cac tgc ctc cgg cct agg tgg cag tca gcc tgg tgg cca acc cta gct 1058  
 His Cys Leu Arg Pro Arg Trp Gln Ser Ala Trp Trp Pro Thr Leu Ala  
     -65                  -60                  -55  
 gtt cta gcc ctg ctg agc tgc gtc aca gaa gct tcc ctg gac cca atg 1106  
 Val Leu Ala Leu Leu Ser Cys Val Thr Glu Ala Ser Leu Asp Pro Met  
     -50                  -45                  -40  
 tcc cgc agc ccc gcc gct cgc gac ggt ccc tca ccg gtc ttg gcg ccc 1154  
 Ser Arg Ser Pro Ala Ala Arg Asp Gly Pro Ser Pro Val Leu Ala Pro  
     -35                  -30                  -25  
 ccc acg gac cac ctg cct ggg gga cac act gcg cat ttg tgc agc gaa 1202  
 Pro Thr Asp His Leu Pro Gly Gly His Thr Ala His Leu Cys Ser Glu  
     -20                  -15                  -10                  -5  
 aga acc ctg cga ccc ccg cct cag tct cct cag ccc gca ccc ccg ccg 1250  
 Arg Thr Leu Arg Pro Pro Gln Ser Pro Gln Pro Ala Pro Pro Pro  
     -1                 1                 5                 10  
 cct ggt ccc gcg ctc cag tct cct ccc gct gcg ctc cgc ggg gca cgc 1298  
 Pro Gly Pro Ala Leu Gln Ser Pro Pro Ala Ala Leu Arg Gly Ala Arg  
     15                 20                 25  
 gcg gcg cgt gca gga acc cgg agc agc cgc gca cgg acc aca gat gcg 1346  
 Ala Ala Arg Ala Gly Thr Arg Ser Ser Arg Ala Arg Thr Thr Asp Ala  
     30                 35                 40  
 cgc ggc tgc cgc ctg cgc tcg cag ctg gtg ccg gtg agc gcg ctc ggc 1394  
 Arg Gly Cys Arg Leu Arg Ser Gln Leu Val Pro Val Ser Ala Leu Gly  
     45                 50                 55                 60  
 cta ggc cac agc tcc gac gag ctg ata cgt ttc cgc ttc tgc agc ggc 1442  
 Leu Gly His Ser Ser Asp Glu Leu Ile Arg Phe Arg Phe Cys Ser Gly  
     65                 70                 75  
 tcg tgc cgc cga gca cgc tcc cag cac gat ctc agt ctg gcc agc cta 1490  
 Ser Cys Arg Arg Ala Arg Ser Gln His Asp Leu Ser Leu Ala Ser Leu  
     80                 85                 90  
 ctg ggc gct ggg gcc cta cgg tcg cct ccc ggg tcc ccg ccg atc agc 1538  
 Leu Gly Ala Gly Ala Leu Arg Ser Pro Pro Gly Ser Arg Pro Ile Ser  
     95                 100                 105  
 cag ccc tgc tgc cgg ccc act cgc tat gag gcc gtc tcc ttc atg gac 1586  
 Gln Pro Cys Cys Arg Pro Thr Arg Tyr Glu Ala Val Ser Phe Met Asp  
     110                 115                 120  
 gtg aac agc acc tgg agg acc gtg gac cac ctc tcc gcc act gcc tgc 1634  
 Val Asn Ser Thr Trp Arg Thr Val Asp His Leu Ser Ala Thr Ala Cys  
     125                 130                 135                 140  
 ggc tgt ctg ggc tgaggatgtatctccaa gccttgcac actagacc 1686  
 Gly Cys Leu Gly

tgtgttgcac tacctggaac agctccaccg ggcctcacta accaggagcc tcaaactcagc 1746  
 aggatatgga ggctgcagag ctcaggcccc aggccggta gtgacagacg tcgtcgcat 1806  
 gacagacaga gtgaaagatg tcggaaccac tgaccaacag tcccaagttg ttcatggatc 1866  
 ccagctctac agacaggaga aacctcagct aaagagaact cctctggag aatccagaaa 1926  
 tggccctctg tcctgggaa tgaatttga agagatata atacatata acattgtagt 1986  
 cgcggtgctg gaccagcctg tgctgaaacc agtcccgtgt tcacttgtgg aagccgaagc 2046  
 cctatttatt atttctaaat tatttatttta ctttgaaaaa aaacggccaa gtcggcctcc 2106  
 ctttagtgag ggttaatttgc tgatccccggg 2136

<210> 4  
 <211> 224  
 <212> PRT  
 <213> Murinae gen. sp.

<400> 4				
Met Glu Leu Gly Leu Ala Glu Pro Thr Ala Leu Ser His Cys Leu Arg				
-80	-75	-70	-65	
Pro Arg Trp Gln Ser Ala Trp Trp Pro Thr Leu Ala Val Leu Ala Leu				
-60	-55	-50		
Leu Ser Cys Val Thr Glu Ala Ser Leu Asp Pro Met Ser Arg Ser Pro				
-45	-40	-35		
Ala Ala Arg Asp Gly Pro Ser Pro Val Leu Ala Pro Pro Thr Asp His				
-30	-25	-20		
Leu Pro Gly Gly His Thr Ala His Leu Cys Ser Glu Arg Thr Leu Arg				
-15	-10	-5	-1	
Pro Pro Pro Gln Ser Pro Gln Pro Ala Pro Pro Pro Pro Gly Pro Ala				
1	5	10	15	
Leu Gln Ser Pro Pro Ala Ala Leu Arg Gly Ala Arg Ala Ala Arg Ala				
20	25	30		
Gly Thr Arg Ser Ser Arg Ala Arg Thr Thr Asp Ala Arg Gly Cys Arg				
35	40	45		
Leu Arg Ser Gln Leu Val Pro Val Ser Ala Leu Gly Leu Gly His Ser				
50	55	60		
Ser Asp Glu Leu Ile Arg Phe Arg Phe Cys Ser Gly Ser Cys Arg Arg				
65	70	75	80	
Ala Arg Ser Gln His Asp Leu Ser Leu Ala Ser Leu Leu Gly Ala Gly				
85	90	95		
Ala Leu Arg Ser Pro Pro Gly Ser Arg Pro Ile Ser Gln Pro Cys Cys				
100	105	110		
Arg Pro Thr Arg Tyr Glu Ala Val Ser Phe Met Asp Val Asn Ser Thr				
115	120	125		
Trp Arg Thr Val Asp His Leu Ser Ala Thr Ala Cys Gly Cys Leu Gly				
130	135	140		

<210> 5  
<211> 224  
<212> PRT  
<213> Rattus sp.

<220>  
<221> SIGNAL  
<222> (1) .. (39)

<220>  
<221> PROPEP  
<222> (40) .. (80)

<220>  
<221> PEPTIDE  
<222> (81) .. (224)

<220>  
<221> PEPTIDE  
<222> (109) .. (224)

<220>  
<221> PEPTIDE  
<222> (112) .. (224)

<220>  
<221> CARBOHYD  
<222> (206)

<220>  
<221> DISULFID  
<222> (127) .. (192)

<220>  
<221> DISULFID  
<222> (154) .. (220)

<220>  
<221> DISULFID  
<222> (158) .. (222)

<220>  
<221> DISULFID  
<222> (191)  
<223> Interchain disulfide link

<400> 5  
Met Glu Leu Gly Leu Gly Glu Pro Thr Ala Leu Ser His Cys Leu Arg  
1 5 10 15

Pro Arg Trp Gln Pro Ala Leu Trp Pro Thr Leu Ala Ala Leu Ala Leu  
20 25 30

Leu Ser Ser Val Thr Glu Ala Ser Leu Asp Pro Met Ser Arg Ser Pro  
35 40 45

Ala Ser Arg Asp Val Pro Ser Pro Val Leu Ala Pro Pro Thr Asp Tyr  
50 55 60

Leu Pro Gly Gly His Thr Ala His Leu Cys Ser Glu Arg Ala Leu Arg  
65 70 75 80

Pro	Pro	Pro	Gln	Ser	Pro	Gln	Pro	Ala	Pro	Pro	Pro	Pro	Gly	Pro	Ala
					85				90					95	
Leu	Gln	Ser	Pro	Pro	Ala	Ala	Leu	Arg	Gly	Ala	Arg	Ala	Ala	Arg	Ala
					100			105				110			
Gly	Thr	Arg	Ser	Ser	Arg	Ala	Arg	Ala	Thr	Asp	Ala	Arg	Gly	Cys	Arg
					115			120			125				
Leu	Arg	Ser	Gln	Leu	Val	Pro	Val	Ser	Ala	Leu	Gly	Leu	Gly	His	Ser
					130			135			140				
Ser	Asp	Glu	Leu	Ile	Arg	Phe	Arg	Phe	Cys	Ser	Gly	Ser	Cys	Arg	Arg
					145			150			155			160	
Ala	Arg	Ser	Pro	His	Asp	Leu	Ser	Leu	Ala	Ser	Leu	Leu	Gly	Ala	Gly
					165			170				175			
Ala	Leu	Arg	Ser	Pro	Pro	Gly	Ser	Arg	Pro	Ile	Ser	Gln	Pro	Cys	Cys
					180			185				190			
Arg	Pro	Thr	Arg	Tyr	Glu	Ala	Val	Ser	Phe	Met	Asp	Val	Asn	Ser	Thr
					195			200			205				
Trp	Arg	Thr	Val	Asp	His	Leu	Ser	Ala	Thr	Ala	Cys	Gly	Cys	Leu	Gly
					210			215			220				

<210> 6  
<211> 197  
<212> PRT  
<213> *Homo sapiens*

```

<400> 6
Met Gln Arg Trp Lys Ala Ala Ala Leu Ala Ser Val Leu Cys Ser Ser
      1           5           10          15

Val Leu Ser Ile Trp Met Cys Arg Glu Gly Leu Leu Leu Ser His Arg
      20          25          30

Leu Gly Pro Ala Leu Val Pro Leu His Arg Leu Pro Arg Thr Leu Asp
      35          40          45

Ala Arg Ile Ala Arg Leu Ala Gln Tyr Arg Ala Leu Leu Gln Gly Ala
      50          55          60

Pro Asp Ala Met Glu Leu Arg Glu Leu Thr Pro Trp Ala Gly Arg Pro
      65          70          75          80

Pro Gly Pro Arg Arg Arg Ala Gly Pro Arg Arg Arg Arg Ala Arg Ala
      85          90          95

Arg Leu Gly Ala Arg Pro Cys Gly Leu Arg Glu Leu Glu Val Arg Val
      100         105         110

Ser Glu Leu Gly Leu Gly Tyr Ala Ser Asp Glu Thr Val Leu Phe Arg
      115         120         125

Tyr Cys Ala Gly Ala Cys Glu Ala Ala Arg Val Tyr Asp Leu Gly
      130         135         140

```

Leu Arg Arg Leu Arg Gln Arg Arg Arg Leu Arg Arg Glu Arg Val Arg  
 145 150 155 160

Ala Gln Pro Cys Cys Arg Pro Thr Ala Tyr Glu Asp Glu Val Ser Phe  
 165 170 175

Leu Asp Ala His Ser Arg Tyr His Thr Val His Glu Leu Ser Ala Arg  
 180 185 190

Glu Cys Ala Cys Val  
 195

<210> 7

<211> 156

<212> PRT

<213> Homo sapiens

<400> 7

Met Ala Val Gly Lys Phe Leu Leu Gly Ser Leu Leu Leu Leu Ser Leu  
 1 5 10 15

Gln Leu Gly Gln Gly Trp Gly Pro Asp Ala Arg Gly Val Pro Val Ala  
 20 25 30

Asp Gly Glu Phe Ser Ser Glu Gln Val Ala Lys Ala Gly Gly Thr Trp  
 35 40 45

Leu Gly Thr His Arg Pro Leu Ala Arg Leu Arg Arg Ala Leu Ser Gly  
 50 55 60

Pro Cys Gln Leu Trp Ser Leu Thr Leu Ser Val Ala Glu Leu Gly Leu  
 65 70 75 80

Gly Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala Gly Ser  
 85 90 95

Cys Pro Arg Gly Ala Arg Thr Gln His Gly Leu Ala Leu Ala Arg Leu  
 100 105 110

Gln Gly Gln Gly Arg Ala His Gly Gly Pro Cys Cys Arg Pro Thr Arg  
 115 120 125

Tyr Thr Asp Val Ala Phe Leu Asp Asp Arg His Arg Trp Gln Arg Leu  
 130 135 140

Pro Gln Leu Ser Ala Ala Ala Cys Gly Cys Gly Gly  
 145 150 155

<210> 8

<211> 211

<212> PRT

<213> Homo sapiens

<400> 8

Met Lys Leu Trp Asp Val Val Ala Val Cys Leu Val Leu Leu His Thr  
 1 5 10 15

Ala Ser Ala Phe Pro Leu Pro Ala Gly Lys Arg Pro Pro Glu Ala Pro  
 20 25 30

Ala Glu Asp Arg Ser Leu Gly Arg Arg Ala Pro Phe Ala Leu Ser

35	40	45
Ser Asp Ser Asn Met Pro Glu Asp Tyr Pro Asp Gln Phe Asp Asp Val		
50	55	60
Met Asp Phe Ile Gln Ala Thr Ile Lys Arg Leu Lys Arg Ser Pro Asp		
65	70	75
Lys Gln Met Ala Val Leu Pro Arg Arg Glu Arg Asn Arg Gln Ala Ala		
85	90	95
Ala Ala Asn Pro Glu Asn Ser Arg Gly Lys Gly Arg Arg Gly Gln Arg		
100	105	110
Gly Lys Asn Arg Gly Cys Val Leu Thr Ala Ile His Leu Asn Val Thr		
115	120	125
Asp Leu Gly Leu Gly Tyr Glu Thr Lys Glu Glu Leu Ile Phe Arg Tyr		
130	135	140
Cys Ser Gly Ser Cys Asp Ala Ala Glu Thr Thr Tyr Asp Lys Ile Leu		
145	150	155
Lys Asn Leu Ser Arg Asn Arg Arg Leu Val Ser Asp Lys Val Gly Gln		
165	170	175
Ala Cys Cys Arg Pro Ile Ala Phe Asp Asp Asp Leu Ser Phe Leu Asp		
180	185	190
Asp Asn Leu Val Tyr His Ile Leu Arg Lys His Ser Ala Lys Arg Cys		
195	200	205
Gly Cys Ile		
210		

<210> 9  
<211> 39  
<212> DNA  
<213> Homo sapiens

<400> 9  
aaggaaaaaa gcggccgcca tggaacttgg acttggagg 39

<210> 10  
<211> 39  
<212> DNA  
<213> Homo sapiens

<400> 10  
tttttcctt ggccgcgtc cagcccaggc agccgcagg 39

<210> 11  
<211> 140  
<212> PRT  
<213> Homo sapiens

<220>  
<221> CARBOHYD  
<222> (122)  
<223> glycosylated asparagine

<400> 11  
 Pro Pro Pro Gln Pro Ser Arg Pro Ala Pro Pro Pro Pro Ala Pro Pro  
 1 5 10 15  
 Ser Ala Leu Pro Arg Gly Gly Arg Ala Ala Arg Ala Gly Gly Pro Gly  
 20 25 30  
 Ser Arg Ala Arg Ala Ala Gly Ala Arg Gly Cys Arg Leu Arg Ser Gln  
 35 40 45  
 Leu Val Pro Val Arg Ala Leu Gly Leu Gly His Arg Ser Asp Glu Leu  
 50 55 60  
 Val Arg Phe Arg Phe Cys Ser Gly Ser Cys Arg Arg Ala Arg Ser Pro  
 65 70 75 80  
 His Asp Leu Ser Leu Ala Ser Leu Leu Gly Ala Gly Ala Leu Arg Pro  
 85 90 95  
 Pro Pro Gly Ser Arg Pro Val Ser Gln Pro Cys Cys Arg Pro Thr Arg  
 100 105 110  
 Tyr Glu Ala Val Ser Phe Met Asp Val Asn Ser Thr Trp Arg Thr Val  
 115 120 125  
 Asp Arg Leu Ser Ala Thr Ala Cys Gly Cys Leu Gly  
 130 135 140

<210> 12  
<211> 116  
<212> PRT  
<213> Homo sapiens

<220>  
<221> CARBOHYD  
<222> (98)  
<223> glycosylated asparagine

<400> 12  
 Ala Ala Arg Ala Gly Gly Pro Gly Ser Arg Ala Arg Ala Ala Gly Ala  
 1 5 10 15  
 Arg Gly Cys Arg Leu Arg Ser Gln Leu Val Pro Val Arg Ala Leu Gly  
 20 25 30  
 Leu Gly His Arg Ser Asp Glu Leu Val Arg Phe Arg Phe Cys Ser Gly  
 35 40 45  
 Ser Cys Arg Arg Ala Arg Ser Pro His Asp Leu Ser Leu Ala Ser Leu  
 50 55 60  
 Leu Gly Ala Gly Ala Leu Arg Pro Pro Pro Gly Ser Arg Pro Val Ser  
 65 70 75 80  
 Gln Pro Cys Cys Arg Pro Thr Arg Tyr Glu Ala Val Ser Phe Met Asp  
 85 90 95  
 Val Asn Ser Thr Trp Arg Thr Val Asp Arg Leu Ser Ala Thr Ala Cys  
 100 105 110  
 Gly Cys Leu Gly  
 115

<210> 13  
<211> 113  
<212> PRT  
<213> Homo sapiens

<220>  
<221> CARBOHYD  
<222> (95)  
<223> glycosylated asparagine

<400> 13  
Ala Gly Gly Pro Gly Ser Arg Ala Arg Ala Ala Gly Ala Arg Gly Cys  
1 5 10 15  
Arg Leu Arg Ser Gln Leu Val Pro Val Arg Ala Leu Gly Leu Gly His  
20 25 30  
Arg Ser Asp Glu Leu Val Arg Phe Arg Phe Cys Ser Gly Ser Cys Arg  
35 40 45  
Arg Ala Arg Ser Pro His Asp Leu Ser Leu Ala Ser Leu Leu Gly Ala  
50 55 60  
Gly Ala Leu Arg Pro Pro Pro Gly Ser Arg Pro Val Ser Gln Pro Cys  
65 70 75 80  
Cys Arg Pro Thr Arg Tyr Glu Ala Val Ser Phe Met Asp Val Asn Ser  
85 90 95  
Thr Trp Arg Thr Val Asp Arg Leu Ser Ala Thr Ala Cys Gly Cys Leu  
100 105 110  
Gly

<210> 14  
<211> 112  
<212> PRT  
<213> Homo sapiens

<400> 14  
Gly Gly Pro Gly Ser Arg Ala Arg Ala Ala Gly Ala Arg Gly Cys Arg  
1 5 10 15  
Leu Arg Ser Gln Leu Val Pro Val Arg Ala Leu Gly Leu Gly His Arg  
20 25 30  
Ser Asp Glu Leu Val Arg Phe Arg Phe Cys Ser Gly Ser Cys Arg Arg  
35 40 45  
Ala Arg Ser Pro His Asp Leu Ser Leu Ala Ser Leu Leu Gly Ala Gly  
50 55 60  
Ala Leu Arg Pro Pro Pro Gly Ser Arg Pro Val Ser Gln Pro Cys Cys  
65 70 75 80  
Arg Pro Thr Arg Tyr Glu Ala Val Ser Phe Met Asp Val Asn Ser Thr  
85 90 95  
Trp Arg Thr Val Asp Arg Leu Ser Ala Thr Ala Cys Gly Cys Leu Gly  
100 105 110

<210> 15  
<211> 111  
<212> PRT  
<213> Homo sapiens

<400> 15  
Gly Pro Gly Ser Arg Ala Arg Ala Ala Gly Ala Arg Gly Cys Arg Leu  
1 5 10 15  
Arg Ser Gln Leu Val Pro Val Arg Ala Leu Gly Leu Gly His Arg Ser  
20 25 30  
Asp Glu Leu Val Arg Phe Arg Phe Cys Ser Gly Ser Cys Arg Arg Ala  
35 40 45  
Arg Ser Pro His Asp Leu Ser Leu Ala Ser Leu Leu Gly Ala Gly Ala  
50 55 60  
Leu Arg Pro Pro Pro Gly Ser Arg Pro Val Ser Gln Pro Cys Cys Arg  
65 70 75 80  
Pro Thr Arg Tyr Glu Ala Val Ser Phe Met Asp Val Asn Ser Thr Trp  
85 90 95  
Arg Thr Val Asp Arg Leu Ser Ala Thr Ala Cys Gly Cys Leu Gly  
100 105 110

<210> 16  
<211> 110  
<212> PRT  
<213> Homo sapiens

<400> 16  
Pro Gly Ser Arg Ala Arg Ala Ala Gly Ala Arg Gly Cys Arg Leu Arg  
1 5 10 15  
Ser Gln Leu Val Pro Val Arg Ala Leu Gly Leu Gly His Arg Ser Asp  
20 25 30  
Glu Leu Val Arg Phe Arg Phe Cys Ser Gly Ser Cys Arg Arg Ala Arg  
35 40 45  
Ser Pro His Asp Leu Ser Leu Ala Ser Leu Leu Gly Ala Gly Ala Leu  
50 55 60  
Arg Pro Pro Pro Gly Ser Arg Pro Val Ser Gln Pro Cys Cys Arg Pro  
65 70 75 80  
Thr Arg Tyr Glu Ala Val Ser Phe Met Asp Val Asn Ser Thr Trp Arg  
85 90 95  
Thr Val Asp Arg Leu Ser Ala Thr Ala Cys Gly Cys Leu Gly  
100 105 110

<210> 17  
<211> 109  
<212> PRT  
<213> Homo sapiens

<400> 17  
 Gly Ser Arg Ala Arg Ala Ala Gly Ala Arg Gly Cys Arg Leu Arg Ser  
 1 5 10 15  
 Gln Leu Val Pro Val Arg Ala Leu Gly Leu Gly His Arg Ser Asp Glu  
 20 25 30  
 Leu Val Arg Phe Arg Phe Cys Ser Gly Ser Cys Arg Arg Ala Arg Ser  
 35 40 45  
 Pro His Asp Leu Ser Leu Ala Ser Leu Leu Gly Ala Gly Ala Leu Arg  
 50 55 60  
 Pro Pro Pro Gly Ser Arg Pro Val Ser Gln Pro Cys Cys Arg Pro Thr  
 65 70 75 80  
 Arg Tyr Glu Ala Val Ser Phe Met Asp Val Asn Ser Thr Trp Arg Thr  
 85 90 95  
 Val Asp Arg Leu Ser Ala Thr Ala Cys Gly Cys Leu Gly  
 100 105

<210> 18  
<211> 108  
<212> PRT  
<213> Homo sapiens  
<400> 18  
 Ser Arg Ala Arg Ala Ala Gly Ala Arg Gly Cys Arg Leu Arg Ser Gln  
 1 5 10 15  
 Leu Val Pro Val Arg Ala Leu Gly Leu Gly His Arg Ser Asp Glu Leu  
 20 25 30  
 Val Arg Phe Arg Phe Cys Ser Gly Ser Cys Arg Arg Ala Arg Ser Pro  
 35 40 45  
 His Asp Leu Ser Leu Ala Ser Leu Leu Gly Ala Gly Ala Leu Arg Pro  
 50 55 60  
 Pro Pro Gly Ser Arg Pro Val Ser Gln Pro Cys Cys Arg Pro Thr Arg  
 65 70 75 80  
 Tyr Glu Ala Val Ser Phe Met Asp Val Asn Ser Thr Trp Arg Thr Val  
 85 90 95  
 Asp Arg Leu Ser Ala Thr Ala Cys Gly Cys Leu Gly  
 100 105

<210> 19  
<211> 107  
<212> PRT  
<213> Homo sapiens  
<400> 19  
 Arg Ala Arg Ala Ala Gly Ala Arg Gly Cys Arg Leu Arg Ser Gln Leu  
 1 5 10 15  
 Val Pro Val Arg Ala Leu Gly Leu Gly His Arg Ser Asp Glu Leu Val  
 20 25 30

Arg Phe Arg Phe Cys Ser Gly Ser Cys Arg Arg Ala Arg Ser Pro His  
 35                   40                   45

Asp Leu Ser Leu Ala Ser Leu Leu Gly Ala Gly Ala Leu Arg Pro Pro  
 50                   55                   60

Pro Gly Ser Arg Pro Val Ser Gln Pro Cys Cys Arg Pro Thr Arg Tyr  
 65                   70                   75                   80

Glu Ala Val Ser Phe Met Asp Val Asn Ser Thr Trp Arg Thr Val Asp  
 85                   90                   95

Arg Leu Ser Ala Thr Ala Cys Gly Cys Leu Gly  
 100               105

<210> 20

<211> 106

<212> PRT

<213> Homo sapiens

<400> 20

Ala Arg Ala Ala Gly Ala Arg Gly Cys Arg Leu Arg Ser Gln Leu Val  
 1                   5                   10                   15

Pro Val Arg Ala Leu Gly Leu Gly His Arg Ser Asp Glu Leu Val Arg  
 20               25                   30

Phe Arg Phe Cys Ser Gly Ser Cys Arg Arg Ala Arg Ser Pro His Asp  
 35               40                   45

Leu Ser Leu Ala Ser Leu Leu Gly Ala Gly Ala Leu Arg Pro Pro Pro  
 50               55                   60

Gly Ser Arg Pro Val Ser Gln Pro Cys Cys Arg Pro Thr Arg Tyr Glu  
 65               70                   75                   80

Ala Val Ser Phe Met Asp Val Asn Ser Thr Trp Arg Thr Val Asp Arg  
 85               90                   95

Leu Ser Ala Thr Ala Cys Gly Cys Leu Gly  
 100               105

<210> 21

<211> 105

<212> PRT

<213> Homo sapiens

<400> 21

Arg Ala Ala Gly Ala Arg Gly Cys Arg Leu Arg Ser Gln Leu Val Pro  
 1               5                   10                   15

Val Arg Ala Leu Gly Leu Gly His Arg Ser Asp Glu Leu Val Arg Phe  
 20               25                   30

Arg Phe Cys Ser Gly Ser Cys Arg Arg Ala Arg Ser Pro His Asp Leu  
 35               40                   45

Ser Leu Ala Ser Leu Leu Gly Ala Gly Ala Leu Arg Pro Pro Pro Gly  
 50               55                   60

Ser Arg Pro Val Ser Gln Pro Cys Cys Arg Pro Thr Arg Tyr Glu Ala  
 65               70                   75                   80

Val Ser Phe Met Asp Val Asn Ser Thr Trp Arg Thr Val Asp Arg Leu  
 85 90 95

Ser Ala Thr Ala Cys Gly Cys Leu Gly  
 100 105

<210> 22  
<211> 104  
<212> PRT  
<213> Homo sapiens

<400> 22  
Ala Ala Gly Ala Arg Gly Cys Arg Leu Arg Ser Gln Leu Val Pro Val  
 1 5 10 15

Arg Ala Leu Gly Leu Gly His Arg Ser Asp Glu Leu Val Arg Phe Arg  
 20 25 30

Phe Cys Ser Gly Ser Cys Arg Arg Ala Arg Ser Pro His Asp Leu Ser  
 35 40 45

Leu Ala Ser Leu Leu Gly Ala Gly Ala Leu Arg Pro Pro Pro Gly Ser  
 50 55 60

Arg Pro Val Ser Gln Pro Cys Cys Arg Pro Thr Arg Tyr Glu Ala Val  
 65 70 75 80

Ser Phe Met Asp Val Asn Ser Thr Trp Arg Thr Val Asp Arg Leu Ser  
 85 90 95

Ala Thr Ala Cys Gly Cys Leu Gly  
 100

<210> 23  
<211> 103  
<212> PRT  
<213> Homo sapiens

<400> 23  
Ala Gly Ala Arg Gly Cys Arg Leu Arg Ser Gln Leu Val Pro Val Arg  
 1 5 10 15

Ala Leu Gly Leu Gly His Arg Ser Asp Glu Leu Val Arg Phe Arg Phe  
 20 25 30

Cys Ser Gly Ser Cys Arg Arg Ala Arg Ser Pro His Asp Leu Ser Leu  
 35 40 45

Ala Ser Leu Leu Gly Ala Gly Ala Leu Arg Pro Pro Pro Gly Ser Arg  
 50 55 60

Pro Val Ser Gln Pro Cys Cys Arg Pro Thr Arg Tyr Glu Ala Val Ser  
 65 70 75 80

Phe Met Asp Val Asn Ser Thr Trp Arg Thr Val Asp Arg Leu Ser Ala  
 85 90 95

Thr Ala Cys Gly Cys Leu Gly  
 100

<210> 24  
<211> 102  
<212> PRT  
<213> Homo sapiens

<400> 24  
Gly Ala Arg Gly Cys Arg Leu Arg Ser Gln Leu Val Pro Val Arg Ala  
1 5 10 15  
Leu Gly Leu Gly His Arg Ser Asp Glu Leu Val Arg Phe Arg Phe Cys  
20 25 30  
Ser Gly Ser Cys Arg Arg Ala Arg Ser Pro His Asp Leu Ser Leu Ala  
35 40 45  
Ser Leu Leu Gly Ala Gly Ala Leu Arg Pro Pro Gly Ser Arg Pro  
50 55 60  
Val Ser Gln Pro Cys Cys Arg Pro Thr Arg Tyr Glu Ala Val Ser Phe  
65 70 75 80  
Met Asp Val Asn Ser Thr Trp Arg Thr Val Asp Arg Leu Ser Ala Thr  
85 90 95  
Ala Cys Gly Cys Leu Gly  
100

<210> 25  
<211> 101  
<212> PRT  
<213> Homo sapiens

<400> 25  
Ala Arg Gly Cys Arg Leu Arg Ser Gln Leu Val Pro Val Arg Ala Leu  
1 5 10 15  
Gly Leu Gly His Arg Ser Asp Glu Leu Val Arg Phe Arg Phe Cys Ser  
20 25 30  
Gly Ser Cys Arg Arg Ala Arg Ser Pro His Asp Leu Ser Leu Ala Ser  
35 40 45  
Leu Leu Gly Ala Gly Ala Leu Arg Pro Pro Gly Ser Arg Pro Val  
50 55 60  
Ser Gln Pro Cys Cys Arg Pro Thr Arg Tyr Glu Ala Val Ser Phe Met  
65 70 75 80  
Asp Val Asn Ser Thr Trp Arg Thr Val Asp Arg Leu Ser Ala Thr Ala  
85 90 95  
Cys Gly Cys Leu Gly  
100

<210> 26  
<211> 100  
<212> PRT  
<213> Homo sapiens

<400> 26  
Arg Gly Cys Arg Leu Arg Ser Gln Leu Val Pro Val Arg Ala Leu Gly  
1 5 10 15

Leu Gly His Arg Ser Asp Glu Leu Val Arg Phe Arg Phe Cys Ser Gly  
20 25 30

Ser Cys Arg Arg Ala Arg Ser Pro His Asp Leu Ser Leu Ala Ser Leu  
35 40 45

Leu Gly Ala Gly Ala Leu Arg Pro Pro Pro Gly Ser Arg Pro Val Ser  
50 55 60

Gln Pro Cys Cys Arg Pro Thr Arg Tyr Glu Ala Val Ser Phe Met Asp  
65 70 75 80

Val Asn Ser Thr Trp Arg Thr Val Asp Arg Leu Ser Ala Thr Ala Cys  
85 90 95

Gly Cys Leu Gly  
100

<210> 27

<211> 99

<212> PRT

<213> Homo sapiens

<400> 27

Gly Cys Arg Leu Arg Ser Gln Leu Val Pro Val Arg Ala Leu Gly Leu  
1 5 10 15

Gly His Arg Ser Asp Glu Leu Val Arg Phe Arg Phe Cys Ser Gly Ser  
20 25 30

Cys Arg Arg Ala Arg Ser Pro His Asp Leu Ser Leu Ala Ser Leu Leu  
35 40 45

Gly Ala Gly Ala Leu Arg Pro Pro Pro Gly Ser Arg Pro Val Ser Gln  
50 55 60

Pro Cys Cys Arg Pro Thr Arg Tyr Glu Ala Val Ser Phe Met Asp Val  
65 70 75 80

Asn Ser Thr Trp Arg Thr Val Asp Arg Leu Ser Ala Thr Ala Cys Gly  
85 90 95

Cys Leu Gly

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
10 October 2002 (10.10.2002)

PCT

(10) International Publication Number  
**WO 02/078730 A3**

(51) International Patent Classification<sup>7</sup>: A61K 38/18,  
38/16, A61P 25/02

(74) Agent: **ELRIFI, Ivor, R.**; Mintz, Levin, Cohn, Ferris,  
Glovsky and Popeo, P.C., One Financial Center, Boston,  
MA 02111 (US).

(21) International Application Number: PCT/US02/06388

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 28 February 2002 (28.02.2002)

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).

(25) Filing Language: English

(26) Publication Language: English

Published:

— with international search report

(30) Priority Data:

60/287,554 28 March 2001 (28.03.2001) US  
09/820,421 28 March 2001 (28.03.2001) US

(63) Related by continuation (CON) or continuation-in-part  
(CIP) to earlier application:

US 09/820,421 (CIP)  
Filed on 28 March 2001 (28.03.2001)

(71) Applicant (for all designated States except US): **BIOGEN,  
INC.** [US/US]; 14 Cambridge Center, Cambridge, Massa-  
chusetts 02142 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **SAH, Dinah, W., Y.**  
[US/US]; 4 Longfellow Place, Apt. 2608, Boston, MA  
02114 (US).

(88) Date of publication of the international search report:  
27 November 2003

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

WO 02/078730 A3

(54) Title: USE OF NEUBLASTIN POLYPEPTIDES FOR TREATING NEUROPATHIC PAIN

(57) Abstract: The invention relates to treatments of neuropathic pain, including tactile allodynia, and to treatments for reducing loss of pain sensitivity associated with neurophathy. The present treatments involve the use of neublastin (NBN) polypeptides.

# INTERNATIONAL SEARCH REPORT

Int'l Application No  
PCT/US 02/06388

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/18 A61K38/16 A61P25/02

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BIOSIS, MEDLINE, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 02 060929 A (SAH DINAH W Y ;BIOGEN INC (US); BORJACK-SJODIN PAULA ANN (US); MIL) 8 August 2002 (2002-08-08) * see claims 1 and 25-26, pages 17-18 and 22-24, example 4 * ---	1-12, 40-56
E	WO 02 072826 A (JOHANSEN TEIT E ;NS GENE AS (DK); SAH DINAH WEN YEE (US); BIOGEN I) 19 September 2002 (2002-09-19) * see claims 1,5,44-45, page 2, pages 6-7, page 39 and example 9 * ---	1-12, 40-56
E	WO 02 051433 A (GENENTECH INC ;SHELTON DAVID L (US); PHILLIPS HEIDI S (US)) 4 July 2002 (2002-07-04) * see claims 1,4,14,21, pages 8-9, page 59 * ---	1-12, 40-56

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

8 April 2003

17. 04. 03

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Merckling, V

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 02/06388

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 04050 A (GEERTS HUGO ALFONSO ; MASURE STEFAN LEO JOZEF (BE); CIK MIROSLAV (B) 27 January 2000 (2000-01-27) * see claim 59, pages 12-13, pages 24-25, page 27 and example 9 *	1-12, 40-56
Y	---	1-56
X	WO 00 01815 A (BLOM NIKOLAJ ; HANSEN CLAUS (DK); JOHANSEN TEIT E (DK); NEUROSEARCH) 13 January 2000 (2000-01-13)	1-12, 40-56
Y	* see claims 23-24, fig.24, pages 59-64 *	1-56
Y	---	
X	WO 00 18799 A (MILBRANDT JEFFREY D ; BALOH ROBERT H (US); UNIV WASHINGTON (US)) 6 April 2000 (2000-04-06)	1-12, 40-56
Y	* see page 6 line 20 to page 7 line 4, page 38 lines 4-25, claim 38 *	1-56
Y	---	
X	WO 00 34475 A (ASUNCION FRANKLIN J ; SIMONET WILLIAM SCOTT (US); AMGEN INC (US); J) 15 June 2000 (2000-06-15)	1-12, 40-56
Y	* see page 5, fig.7, pages 24-25 and page 67 *	1-56
Y	---	
Y	BOUCHER T J ET AL: "ARTEMIN PREVENTS INJURY-INDUCED CHANGES IN SMALL SENSORY NEURONS" ABSTRACTS OF THE SOCIETY FOR NEUROSCIENCE, SOCIETY FOR NEUROSCIENCE, WASHINGTON, DC, US, vol. 26, no. 1/2, 4 November 2000 (2000-11-04), page 63305 XP001121845 ISSN: 0190-5295 * abstract *	1-56
	-----	

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 02/06388

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  

Although claims 1–56 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.
2.  Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-39, 52-56

Use of a neublastin polypeptide for treating neuropathic pain, such as for example tactile allodynia.

2. Claims: 40-51

Use of neublastin polypeptides for reducing loss of pain sensitivity in a subject afflicted with neuropathy.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 02/06388

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 02060929	A	08-08-2002	WO	02060929 A2		08-08-2002
WO 02072826	A	19-09-2002	US	2002055467 A1		09-05-2002
			WO	02072826 A2		19-09-2002
WO 02051433	A	04-07-2002	WO	02051433 A2		04-07-2002
WO 0004050	A	27-01-2000	AU	5283299 A		07-02-2000
			BG	105107 A		31-10-2001
			BR	9912819 A		02-05-2001
			CA	2333910 A1		27-01-2000
			CN	1342165 T		27-03-2002
			CZ	20010028 A3		15-08-2001
			WO	0004050 A2		27-01-2000
			EP	1097167 A2		09-05-2001
			HR	20010036 A1		31-12-2001
			HU	0102821 A2		28-11-2001
			JP	2002520042 T		09-07-2002
			NO	20010212 A		14-03-2001
			PL	348431 A1		20-05-2002
			SK	142001 A3		05-02-2002
			TR	200100074 T2		21-11-2001
WO 0001815	A	13-01-2000	AU	755114 B2		05-12-2002
			AU	4769399 A		24-01-2000
			BR	9911908 A		27-03-2001
			CA	2336218 A1		13-01-2000
			CN	1311818 T		05-09-2001
			WO	0001815 A2		13-01-2000
			EE	200100008 A		17-06-2002
			EP	1095140 A2		02-05-2001
			HU	0103758 A2		28-01-2002
			JP	2002519061 T		02-07-2002
			NO	20010088 A		06-03-2001
			PL	345950 A1		14-01-2002
			TR	200100056 T2		21-11-2001
			US	2002055467 A1		09-05-2002
WO 0018799	A	06-04-2000	AU	6405499 A		17-04-2000
			CA	2343927 A1		06-04-2000
			EP	1028975 A1		23-08-2000
			JP	2002534957 T		22-10-2002
			WO	0018799 A1		06-04-2000
			US	6284540 B1		04-09-2001
			US	2002002269 A1		03-01-2002
WO 0034475	A	15-06-2000	AU	2354600 A		26-06-2000
			EP	1137774 A2		04-10-2001
			JP	2002531128 T		24-09-2002
			WO	0034475 A2		15-06-2000